Tong Ren Tang Chinese Medicine Announces 2024 Interim Results

August 30, 2024
HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) Beijing Tong Ren Tang Chinese Medicine Company Limited (“Tong Ren Tang Chinese Medicine” or the “Company”, Stock code: 3613.HK) is pleased to announce the unaudited results of the Company and its subsidiaries (collectively referred to as the “Group”) for the six months ended 30 June 2024 (the “Period”).In the first half of 2024, facing challenges such as the sustained strength of the Hong Kong dollar, changing consumption patterns, and a sluggish retail industry in Hong Kong, China and Macau, China regions, the Group responded proactively and made simultaneous efforts from multiple dimensions of products, marketing, research and development, and production. This ensured the stable operation of its business and the continued consolidation of its market-leading position. During the Period, the Group achieved revenue of HK$ 664.5 million, net profit of HK$ 240.3 million, and profit attributable to owners of HK$ 219.8 million, with earnings per share of HK$ 0.26.By market segment, during the Period, the Group further enriched its product matrix and optimized its retail market layout. The Hong Kong, China market achieved revenue of HK$333.8 million, with 30 retail terminals, a net increase of 3 terminals compared with the previous year. In the markets outside Mainland China (excluding Hong Kong, China,), the Group accelerated its brand market expansion and steadily promoted its internationalization, achieving revenue of HK$214.4 million. In addition, the Group achieved revenue of HK$116.3 million in Mainland China market.Sufficient momentum from technological innovation, new breakthroughs in production and R&DThe development of science and technology has provided new technical support and growth strategies for the advancement of traditional Chinese medicine (“TCM”). During the Period, the Group leveraged technological innovation as a driving force, empowering intelligent upgrades in production and enhancing product excellence and innovation. This has helped accumulate new momentum for future growth and supported the inheritance and innovation of TCM.Product quality is the lifeline of an enterprise. At the production level, the Group’s production and R&D base in Tai Po consistently upholds stringent standards and rigorous procedural controls. The Group has successfully secured Hong Kong, China’s GMP and ISO22000 certifications, with its product quality has been recognized. Additionally, to further enhance the cost competitiveness of its products, the Group has intensified efforts in revamping and upgrading its production layout. By increasing mechanization and automation, the Gorup has effectively reduced production costs and boosted productivity, thereby ensuring consistent product availability in the market.In terms of products, the Group intensifies its R&D efforts, actively diversifying its product matrix and expediting the translation of scientific research outcomes. During the Period, the Group completed the production of a number of new registered proprietary Chinese medicines and health food products, including Guizhi Fuling Wan , Lingzhi Turmeric Compound Blood-supplementing and Nerve-calming Capsules , Wolfberry Coffee Mix , Red Ginseng Coffee Mix and Sporoderm-broken Ganoderma Lucidum Spores Chocolate . The Group also plans to commence the production of Qiyao Pills ) and Jinshui Liujun Jian Granules. In April this year, the Group’s self-developed product, Danggui Buxue Keli, were awarded the Certificate of Registration of Proprietary Chinese Medicines (HKC-18604) issued by the Chinese Medicine Council of Hong Kong, China, further enriching the Group’s product portfolio. In May this year, the Group’s invention patent (Patent Number: ZL 2023 1 1206874.8) for “a freckle-removing and whitening product along with its preparation method and uses was successfully granted by China National Intellectual Property Administration and has been applied to Ageing-Defying Collection of the Tong Ren Tang’s Chinese anti-aging NMN series.In addition to preserving and advancing TCM services, the Group is also expanding into new health concept areas. During the Period, the Group entered into a Memorandum of Understanding with Deer Industry New Zealand to promote innovative health-functional deer food products, assisting both parties in collaborative development, registration and marketing efforts. The Group will give full play to strengths in both its proprietary brand and Chinese medicine, combined with the resource advantages provided by New Zealand, the origin of deer velvet, to accelerate the R&D of New Zealand deer products and the deployment of the industrial chain configuration, and continue to expand into new health domains.Moving forward, the Group will continue to strengthen its cooperation with internationally renowned institutions and research organizations such as the University of Hong Kong, Hong Kong Baptist University and the University of California, to conduct research on the safety and mechanism of key products such as Tong Ren Tang’s Angong Niuhuang Wan , Ganoderma Lucidum-related products and Tong Ren Niu Huang Qing Xin Wan, in order to further expand its scientific research results, and to provide a reliable scientific basis for the entry of its products into the mainstream markets overseas in the future. The Group adheres to the highest standards of superior, pure and genuine traditional Chinese medicinal materials, and brings together the essence of the intangible cultural heritage culture and exquisite craftsmanship, as well as strict and meticulous production to fully embody the Group’s motto: “Never cut corners on labour and quality, no matter how complex the process or how costly the materials”. This philosophy not only enhances the health value delivered to customers but also provides the Group with a stronger growth momentum.Orderly market expansion and diversified marketing to strengthen brand effectIn terms of market expansion, on the one hand, the Group has continuously introduced new products to consolidate and expand its market share. During the Period, the Group launched new products, including the Tong Ren Tang’s Chinese anti-aging NMN series – the Youth Prime Collection and the Age-Defying Collection, the Guizhi Fuling Wan , and Wood Lok Medicated Oil , broadening its product range. At the same time, the Group further expanded its retail presence in Hong Kong, China by opening three new retail outlets in North Point, Mong Kok, and West Kowloon. The North Point and West Kowloon stores also offer Chinese medical consultation and treatments to reach a wider customer base.In terms of product marketing, the Group has intensified its marketing efforts to increase product recognition. Specifically targeting the “major variety” products, such as Tong Ren Tang Angong Niuhuang Wan and Sporoderm-broken Ganoderma Lucidum Spores Powder Capsule and Tong Ren Niu Huang Qing Xin Wan, the Group promoted and advertised the brand and products through an omni-channel approach, integrating special festivals and themes to create consumer hotspots. Moreover, the Group has also advanced the development of both online and offline channels, continuously expanding its sales channels to meet the demands of post-pandemic era business models.In terms of brand promotion, the Group capitalized on its participation in major events, significantly enhancing its promotional efforts and accelerating the brand market expansion. During the Period, serving as a critical portal for Beijing Tong Ren Tang’s international development, the Group participated in the 2024 Wuzhen Health Conference, showcasing its flagship products and a variety of new products. In implementing the “Belt and Road” initiative, the Group leads time-honored brands venture into the world and integrates into the international arena. By adopting the “bring in” and “go global” strategy, the Group is promoting the rich and profound TCM culture, further disseminates Chinese health wisdom globally to benefit more people.Additionally, the Group has enhanced its brand image and influence through public welfare activities. The Group has actively encouraged its overseas retail outlets that offer Chinese medical consultations and treatments to provide charity Chinese medicine clinic services. This initiative embodies the Group’s philosophy of “introducing medicine through treatments” and supports its brand development. In Hong Kong, China, the Group has fully supported and participated in public welfare activities, demonstrating to society and the public the Group’s corporate spirit of “Nurturing kindness and virtue, preserving tranquility and wellness ”. Through its services and products, the Group is dedicated to deeply embedding the Tong Ren Tang brand, products and Chinese medical consultation and treatments services into the community, spreading the culture of Tong Ren Tang while encouraging a healthy lifestyle among community residents.Future ProspectsWith the ongoing economic and social development, an intensifying aging population trend, and the increasing health awareness among residents, the pharmaceutical consumption market is expected to expand continuously. TCM, as a crucial sector of the pharmaceutical industry, continues to hold significant potential for growth in the global market.In the future, the Group will continue to strengthen R&D efforts and expand its proprietary product matrix, including products such as Ganoderma Lucidum series and anti-aging series, to create diversified growth engines and drive the realization of high-quality developmental transformation within the Group. At the same time, the Group will focus on business development by enhancing its new retail layout, accelerating the introduction of new products, continuously advancing the registration of Tong Ren Tang’s key products in Vietnam, innovating business models, and reinforcing its core competitive advantages. By leveraging the development of new quality productive forces as its engine, the Group strives to achieve sustained growth in its business scale. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

Wuling Motors’ Net Profit Surges 72.3% in H1 2024

August 30, 2024
HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Liuzhou, a key industrial hub in Southwest China, has long been a pioneer in China's industrial history. From manufacturing Guangxi's first automobile and aircraft before the founding of the People's Republic of China to becoming the second-largest industrial city in South China during the reform era, Liuzhou has consistently thrived with the times.Today, as Chinese automotive companies expand globally, Liuzhou's businesses are once again at the forefront, with Wuling Motors (0305.HK) serving as a prominent example.On August 22, Wuling Motors announced its interim results for 2024, demonstrating strong performance across its three main business segments. The company is actively enhancing its high-quality production capabilities and exploring growth opportunities abroad, achieving impressive results in its international ventures.In the first half of 2024, Wuling Motors made significant strides in its overseas expansion: exporting auto parts to Vietnam, golf carts to Egypt, and new energy logistics vehicles to South Korea, as well as establishing a research and development center in Hong Kong...Wuling Motors is sending a clear message to the world: The company's future is bright, with limitless potential.(I) Moderate Growth in Auto Parts and Other Industrial Services RevenueAccording to Wuling Motors' 2024 interim report, the company achieved a revenue of CNY 3.946 billion in the first half of this year, with a gross profit of CNY 426 million. Net profit surged 72.3% to CNY 21.125 million compared to the same period last year.Breaking down the segments, the auto parts and other industrial services business recorded a revenue of CNY 2.698 billion in the first half of the year, up 6.1% year-on-year. During this period, Wuling Motors focused on consolidating its existing market while aggressively expanding into new territories. The company aimed to break into growth markets dominated by giants like Great Wall Motors, Chery, and BYD. Sales to newly acquired customers surged to CNY 1.042 billion, accounting for 38.6% of the divisional revenue.Wuling's Jingmen base in Hubei, dedicated to supplying Great Wall Motors, rapidly scaled up its production, generating CNY 334 million in revenue in the first half of the year. It successfully delivered frame assemblies for two Great Wall models, breaking the record for the highest first-month delivery of a new product. Additionally, Wuling's domestic ultra-high-strength steel tube hydroforming production line - a first in China - successfully commenced mass production, supplying 13 hydroformed products to premium models from brands like Great Wall and BYD.The auto parts and other industrial services segment posted an operating profit of CNY 75.883 million in the first half of the year, up 44.3% year-on-year.In the automotive power systems segment, Wuling Motors achieved CNY 902 million in revenue. While strengthening its traditional power technology upgrades, Wuling Motors accelerated its layout of new energy power integration development, speeding up its new energy business initiatives. In the first half of 2024, Wuling accelerated the establishment of a comprehensive product matrix for hybrid and battery electric powertrains and core components, advancing production capacity and rolling out new products and technologies. By promoting its products, Wuling Motors has focused on building lines and improving processes for motors, motor controllers, rotors, and stators, securing new energy market collaborations with JAC Motors and Changan Kaicene.The commercial vehicle segment posted CNY 331 million in revenue in the first half of the year, primarily seeking breakthroughs in high-value-added sub-sectors.Wuling Motors achieved a gross profit margin of 10.8% in the first half of 2024, a significant increase of 270 basis points from 8.1% in the same period in 2023. This impressive growth was largely driven by declining prices for raw materials, such as steel. Additionally, the ramp-up of higher-margin products further contributed to the substantial improvement in the company's profitability.(II) Striking the Main Chord of Overseas ExpansionIn the 1960s and 1970s, Liuzhou's tractors were exported to Vietnam and Rwanda in Africa, and in 1990, its microcars were shipped to Thailand. Liuzhou-made vehicles have consistently ventured overseas.Today, Liuzhou's automotive industry faces another historic opportunity for overseas expansion.As domestic market demand becomes saturated, expanding abroad has become essential for Chinese companies, and overseas markets are emerging as the new "blue ocean."For example, Guangxi's exports were robust in the first half of the year. According to customs statistics, Guangxi's import and export trade reached CNY 345.28 billion in the first half of 2024, up 12% year-on-year. Exports alone hit CNY 191.8 billion, a record high, rising 28.5%. Exports of major categories like mechanical and electrical products and labor-intensive products were CNY 109.18 billion and CNY 37.3 billion, respectively, growing by 26.8% and 48.5% and accounting for 56.9% and 19.4% of Guangxi's total exports.In the automotive market, "intense competition" and "overseas expansion" are the current hot topics. According to the China Association of Automobile Manufacturers (CAAM), in July 2024, China exported 469,000 vehicles, up 19.6% year-on-year. From January to July 2024, China's auto exports reached 3.262 million units, up 28.8%. Among these, exports of battery electric vehicles totaled 554,000 units, and plug-in hybrid vehicles reached 154,000 units, representing a 180% increase year-on-year.Specifically in Liuzhou, more than 90,000 vehicles were exported through Liuzhou Customs in the first half, up 23.8% year-on-year; of these, over 10,000 were new energy vehicles (NEVs), a surge of more than 30-fold.Wuling Motors has seized this trend, charting a course for global success.Take the Wuling golf cart as an example. With its strong handling, lightweight design, comfortable ride, and powerful performance, the Wuling golf cart has been highly favored by overseas customers. Since its launch, it has been sold in countries across Southeast Asia, Central Asia, Europe, and America.Earlier this year, Wuling Industrial, a subsidiary of Wuling Motors, showcased its new multi-purpose golf/community vehicles at the 71st PGA Merchandise Show in Orlando, USA, drawing significant attention. On April 15, the 135th Canton Fair kicked off in Guangzhou, where Wuling Industrial's golf carts attracted buyers from 205 countries and regions worldwide. On May 22, Wuling Industrial shipped about 200 golf carts to Egypt, expecting to complete delivery in the third quarter.Wuling Motors' joint venture, Wuling New Energy, also broke new ground with its G050 left-hand drive battery electric logistics vehicle. In March 2024, the company secured its first order of 300 units with South Korea's Daechang Corp, marking a breakthrough in the Korean market.Currently, Wuling's sightseeing vehicles, golf carts, and other products are exported to countries such as Vietnam, Singapore, Thailand, the USA, and Australia. Its new energy logistics vehicles have also penetrated traditional automotive powerhouses or regions such as the USA, Japan, and Europe, laying a solid foundation for expanding into the international market.This achievement is due to Wuling Motors' strategic planning.In recent years, Wuling Motors has accelerated its overseas expansion, with subsidiaries in India and Indonesia continuing to strengthen their presence. These efforts, focused on promoting the localization and launch of new models with key clients, have proven highly effective, helping Wuling penetrate new customer bases and meet international standards.On the product side, Wuling Motors has further enriched its product lineup, with more auto parts poised to enter global markets. In a major breakthrough, Wuling's self-developed rear drive axle assembly and drive system assembly for new energy passenger vehicles successfully entered the overseas market in the first half of this year. This achievement marks a departure from the traditional three-section axle housing structure, instead adopting a hydraulic expansion integral axle housing technology, which has been well-received by customers. On the channel side, Wuling is leveraging Hong Kong as an export conduit for its new energy business, boosting overseas sales for the group and its joint ventures.On the research and development front, Wuling Motors has established an innovation center in Hong Kong and signed memoranda of understanding (MOUs) with Hong Kong Polytechnic University (PolyU) and the Chinese University of Hong Kong (CUHK) to focus on NEV technology, jointly promoting the conversion and application of scientific research results.(III) Driving Global Growth Through High-Quality ProductionIn global competition, technology reigns supreme. Wuling Motors has been a pioneer in the NEV sector, steadfastly pursuing the development of NEVs. With a goal of deriving more than 50% of its business from NEV operations, Wuling is laying a solid foundation to become a front-runner in the new energy vehicle era as it ventures into overseas markets.In the auto parts business, Wuling Motors continues to align with the "passenger-focused" and "electrification" upgrades of its customers' products, continuously developing passenger vehicle products while actively supporting new energy vehicle models for major customers.Currently, Wuling Motors has successfully developed and optimized a range of products, including new energy electric rear axles, motors, motor controllers, range extenders, and hybrid systems. This year, the production of core components such as electric axles and hybrid engines has seen steady growth.After surpassing the milestone of producing one million units of micro electric axles, Wuling's coaxial electric drive axle became the first to achieve commercialization in China. It has been adopted by brands such as Changan Kaicene, Ruichi, and JAC Motors. Wuling Motors also secured orders from leading companies like Chery and Geely for electric axles used in mainstream NEV commercial vehicles. At Wuling's Jingmen base, which supplies auto parts to Great Wall Motors, business has flourished, with over 50% of its products sold in the first half of 2024 being NEV parts, generating CNY 333 million in revenue.In automotive power systems, Wuling Motors has made remarkable progress in developing and mass-producing high-efficiency engines and new energy power systems. Their strategy seamlessly integrates traditional power technology upgrades with new energy power innovations, resulting in a robust product lineup. In the first half of 2024, Wuling Motors focused on enhancing production lines and processes for motors, motor controllers, and rotors and stators. The H-platform ultra-high-efficiency engine has been successfully commercialized, securing projects with NEV clients like JAC, Changan, and Skyworth. Additionally, Wuling's casting sales reached 515,000 units, up 26.2% compared to the same period in 2023.In the commercial vehicle segment, Wuling focuses on specialized modification markets such as cold chain vehicles, sanitation vehicles, and medical vehicles. Their specialty products, including refrigerated trucks, sanitation trucks, and fire trucks, have been delivered to regions like Shandong, Zhejiang, Hunan, and Beijing. Leveraging its customization capabilities, Wuling has partnered with PepsiCo to develop a "mobile new retail" model, delivering over 100 Wuling vending trucks to PepsiCo and accelerating the expansion of mobile commerce.Wuling's joint venture, Wuling New Energy, is actively upgrading its brand and market position. They launched the long-range Golden Storage Mid-size Logistics Vehicle to quickly capture market share, achieving monthly sales exceeding 1,000 units in the first three months after launch. Additionally, Wuling New Energy is aggressively expanding into international markets, increasing exports to countries such as the USA, Japan, and South Korea. In the first half of 2024, Wuling New Energy sold approximately 7,900 NEVs, a 68.1% increase compared to the same period in 2023.It is evident that Wuling Motors' strategic direction is becoming increasingly clear.With a comprehensive business layout and a full range of products, Wuling has created synergies across its industrial chain, positioning itself as Guangxi's most comprehensive leading automotive group in the supply chain. With unparalleled control over product quality, cost, scale, and customer relations, Wuling has built a formidable competitive advantage.As the NEV era rapidly approaches, Wuling Motors is fortifying its dominant businesses, focusing on high-tech, competitive, and high-end flagship auto parts, expanding markets for high-value specialized modified vehicles, and advancing its NEV key parts and vehicle business.With these foundations, Wuling is boldly venturing overseas, aiming for growth through globalization and efficiency in management, poised for even higher-quality development in the new era. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
汇聚科技有限公司公布截至二零二四年六月三十日止中期业绩 ACN Newswire

汇聚科技有限公司公布截至二零二四年六月三十日止中期业绩

August 30, 2024
香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 汇聚科技有限公司（「汇聚科技」，股份代号：1729，连同其子公司合称「集团」）欣然宣布集团截至二零二四年六月三十日止六个月（「本中期期间」）的中期财务业绩。于本中期期间，由于借贷成本居高不下及财政支持撤销等因素，及地缘政治局势紧张和经济割裂加剧带来的影响，全球经济扩张步伐缓慢。尽管如此，本集团仍积极寻求可使其现有业务组合趋向多元化、拓宽收入来源及为本公司股东提升价值的潜在投资机会，从而改善本集团的业务营运及财务状况。其中，受惠于AI热潮，数据中心分部及特种线分部于本中期期间的收益分别大幅增长16.6%及93.6%，盈利能力相对改善。而随着本集团在医疗设备电线业务投放更多关注及精力，以及两座新厂房的建成，大大拓展了医疗设备电线产品的产能及研发能力，该分部收益亦大幅增加166.0%；同时，本集团已于二零二四年七月完成投资两间医疗及保健相关公司。由于该等分部带动利润率转佳，电缆及电线的整体盈利能力亦有所改善。同时，网络电线分部的海外订单持续改善，于本中期期间，该分部收益增加25.1%。综上，集团于本中期期间录得的收益为2,666.1百万港元，较截止二零二三年九月三十日止六个月期间*（「上一个中期期间」）的2,626.7百万港元增加39.4百万港元或1.5%。本中期期间的经营溢利为309.2百万港元，较上一个中期期间的235.1百万港元增加74.1百万港元或31.5%，而本中期期间的经营利润率则由9.0%上升至11.6%。经营溢利增加主要归因于产品组合变动；医疗设备、数据中心及特种线分部的收益上升，而三个市场分部都具有较佳的利润率；及服务器分部收益及利润率下降。于本中期期间，集团每股基本盈利为10.4港仙，较上一个中期期间的7.8港仙增加33.3%。本公司董事会欣然宣派中期股息每股1港仙，总额约为19.5百万港元。 业务回顾集团各个业务分部的营业额的分布如下:业务分部收益（百万港元）收益占比截至二零二四年六月三十日止六个月截至二零二三年九月三十日止六个月变化截至二零二四年六月三十日止六个月截至二零二三年九月三十日止六个月电线组件 数据中心564.4484.116.6%21.2%18.4% 电讯286.5348.6-17.8%10.7%13.3% 医疗设备386.0145.1166.0%14.5%5.5% 工业设备21.312.866.4%0.8%0.5% 汽车68.469.5-1.6%2.6%2.7%数字电线 网络电线614.7491.225.1%23.0%18.7% 特种电线111.557.693.6%4.2%2.2%服务器613.31,017.8-39.7%23.0%38.7%总计2,666.12,626.71.5%100%100%数据中心分部AI的兴起带动了本集团数据中心业务的增长及发展。于本中期期间，由于服务器升级，数据中心分部的收益由上一个中期期间的484.1百万港元增加80.3百万港元或16.6%至本中期期间的564.4百万港元，盈利能力相对改善。该分部的订单于本中期期间维持于较高的出货水平， 并继续是电线组件业务下最高收益的分部。电讯分部于本中期期间，该分部录得的收益为286.5百万港元，较上一个中期期间的348.6百万港元减少17.8%。电讯分部的主要客户位于中国，收益下跌的主要原因为对比上一个中期期间，本中期期间受到中国农历新年假期影响。医疗设备分部于本中期期间，本集团在医疗设备电线业务投放了更多关注及精力，继续扩大其医疗设备客户群，并于本中期期间加强其研发能力。在去年，受惠于昆山汇聚及江西汇聚两座新厂房建成，以及拓展医疗设备电线产品的产能及研发能力，医疗设备分部于本中期期间的收益大幅增加至386.0百万港元，较上一个中期期间的145.1百万港元增加240.9百万港元或166.0%。工业设备分部尽管全球经济复苏步伐较预期慢，不同国家之间仍然存在分歧，加之高利率抑制了经济活动，本集团的工业设备分部仍略有改善。工业设备分部的收益由上一个中期期间的12.8百万港元增加66.4%至本中期期间的21.3百万港元。汽车分部汽车分部于本中期期间的收益为68.4百万港元，较上一个中期期间的收益69.5百万港元轻微减少1.6%。受地缘政治及贸易战影响，汽车配线产品于本中期期间的销售订单维持于较低水平。然而，本集团仍然相信，汽车配线产品有助本集团为其客户提供更广泛的产品组合。为把握电动汽车市场蓬勃发展带来的机遇，本集团新的全资附属公司Linkz Cables Mexico, S. de R.L. de C.V.（「Linkz Mexico」）已在墨西哥成立，以增加其于中国及亚洲以外市场的市场份额。网络电线分部即使不同国家之间的分歧、战争、利率高企、美元走强及通胀偏高等众多负面因素仍然存在，但网络电线分部的海外订单持续改善。网络电线于本中期期间的收益为614.7百万港元，较上 一个中期期间的491.2百万港元增加123.5百万港元或25.1%。铜价上涨反映市场需求持续改善。Linkz Mexico成立后，亦有助增加其于美国及墨西哥市场的市场份额。特种线分部与数据中心分部一样，Al亦刺激特种线分部的高速电缆增长及发展。特种线于本中期期间的收益为111.5百万港元，较上一个中期期间的57.6百万港元显著增加53.9百万港元或93.6%。高速电缆亦带动利润率转佳，为本集团的整体盈利能力带来裨益。服务器分部于本中期期间，服务器的收益为613.3百万港元，较上一个中期期间的1,017.8百万港元减少39.7%。经过去年底新产品出货高峰期之后，今年出现关键部件供应短缺的问题，导致部分订单需要改期。展望展望未来，就不利因素而言，地缘政治局势紧张、高利率持续抑制全球经济活动。根据「国际货币基金组织」于二零二四年发布的 《世界经济展望》最新预测，于二零二三年全球经济增长估计为3.2%，而预期于二零二四年及二零二五年将持续保持相同步伐。五年后全球经济增长的最新预测为3.1%，处于近几十年来的最低水平。而就利好因素而言，随着劳动力参与率提高，通胀下降速度可能较预期中快，致使各国央行可推出宽松计划，提振经济活动。人工智能及较预期更强的结构性改革可带动生产力。尽管本集团正面对宏观经济环境中的相关挑战及困难，管理层仍对其未来业务充满信心。在立讯集团的支持下，本集团在产品制造能力及财务实力方面具有优势。本集团将继续发展战略性业务及市场，巩固其业务基础并于经济低迷时期取得骄人业绩。集团认为，中国持续加快5G技术研发，以及疫情导致的社会新常态，包括居家工作及网络会议等，预计将带动电线组件产品及电讯分部的需求，因此，管理层对5G相关业务充满信心。另一方面，考虑到汽车及电动汽车市场的蓬勃发展，本集团相信，汽车线束产品有助本集团为其客户提供更广泛的产品组合，并通过丰富本集团的业务组合及拓展其独特的客户群，踏足新业务领域。为此，集团已于墨西哥设立一间新的全资附属公司Linkz Mexico，以增加其于中国及亚洲以外市场的市场份额。新厂房预期可于二零二四年下半年投产。新工厂将生产数字电线及汽车配线产品。此乃「中国加一」策略，可保护供应链及出口市场免受地缘政治紧张局势及不可预见的中断影响，令集团能够抓紧这一代5G网络来临及汽车市场所带来的市场机遇。此外，世界各地公司的云技术使用率的不断增加有望推动数据中心的发展。同时，5G发展将推动大数据、物联网、网络游戏及云平台视频流的应用。为把握巨大的市场潜力，本集团已拓展其业务至服务器业务，所提供的产品主要应用于数据中心。考虑到(i)中国正积极开展投资活动以建设数字基础设施；(ii)中国制造商由于地缘政治关系而继续提高本土供应链的比重；及(iii)立讯精密拥有广泛的技术知识及良好的客户关系，本集团对市场的潜在需求持乐观态度。同时，Al的兴起，带动本集团服务器及数据中心分部业务的增长及发展。然而，地缘经济割裂持续加剧，货物、资本及人员流动的障碍不断增加，供应链逐渐出现供应问题。这些都为本集团的业务运作带来了挑战。本集团将尽最大努力寻找任何业务方案，以应对当前经济环境以及全球复杂地缘政治关系，并继续加大及巩固服务器业务的发展。就医疗设备分部而言，集团预计医疗设备电线的需求将继续为集团本年度的医疗设备电线订单带来正面影响。为此，集团已成立两间全资附属公司，分别为汇聚智能科技（昆山）有限公司及江西汇聚精密工业有限公司，以拓展医疗设备电线产品的产能及研发能力。此外，本集团已于二零二四年七月完成投资两间医疗及保健相关公司。一间为具备逾30年良好营运纪录的Cosmic M.E. Inc.（「CME」），于其股份认购后已成为本公司之附属公司。其从事开发、生产及销售电子医疗工具以及其他医疗设备及器材的业务。本集团相信，该认购将使其能利用CME的广泛专业知识及现有生产设施，即时为其现有及新客户提供可靠及优质医疗产品，并为双方就医疗相关产品于研发、生产能力及全球市场扩展方面的发展带来协同效应。另一间为Valkyrie Industries Limited （「Valkyrie」），本公司透过股份认购有权控制其16.75%股份。Valkyrie为一间总部设于英国的初创企业，于触控及虚拟实境术技方面拥有长达七年的专业经验。其已开发能为用户于虚拟仿真场景中创造重量、反抗力及助力的触控科技，并已获得专利权。该项科技结合体适能、健康及游戏，以改善庞大游戏市场的人体表现及神经肌肉复元。本集团认为，Valkyrie的科技将为本集团拓展其产品组合带来机遇，令集团业务更趋多元化，并扩阔其特定客户群的收入来源。此外，新的联络处Time Interconnect America Inc. 已自二零二四年七月起在里地牙哥成立，以抓住更多医疗相关市场的商机。展望未来，考虑到医疗设备市场的需求不断增长，本集团相信该分部将保持其动态增长速度。本集团将在此分部投放更多关注及精力，继续扩大其医疗设备客户群，并加强其研发能力。凭借中国政府的「东数西算」政策，立讯精密将发挥立讯集团的平台优势及市场地位，为本公司引入策略资源，进一步增强本公司在其市场上的持续增长潜力及核心竞争力，使本公司战略发展成为全方位的网络解决方案及基础设施供应商，为股动创造更大的价值。对此，立讯精密正在对本公司的经营及财务状况进行战略检讨，并积极探索本公司内生性及外延式增长和发展的商机。本公司相信，在立讯精密的支持下，本集团将于未来创造更多更多的可能性。- 完 -关于汇聚科技有限公司汇聚科技有限公司是一家信誉卓著的定制电线互连方案供应商，在行业拥有超过30年经验。 总部设于香港，并于中华人民共和国上海、苏州、江西及惠州以及日本及墨西哥拥有生产设施。集团目前制造及供应各种铜缆和光缆电线组件、数字电线产品、医疗产品及服务器产品均根据个别客户伙伴的详述规格及设计而生产。产品已使用在包括电讯、数据中心、工业设备、医疗设备、汽车配线、数字电线及服务器在内的各种市场领域，均受到少商誉优良的中国及国际客户所采用。本新闻稿由智升公关有限公司代表汇聚科技有限公司发放。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
GVRenting Unveils Sustainable Solutions in Urban Architecture SeaPRwire

GVRenting Unveils Sustainable Solutions in Urban Architecture

August 30, 2024
Green Above: How GVRenting’s Urban Farms Are Shaping a New Future in Ho Chi Minh City Ho Chi Minh, Vietnam – August 30, 2024 – (SeaPRwire) – GVRenting (https://www.gvrenting.com) is proud to announce its sustainable solutions in Urban Architecture, which will Shape a New Future in Ho Chi Minh City. In the teeming urban landscape of Ho Chi Minh City, an innovative agricultural revolution is blossoming where one might least expect it: atop the city’s numerous apartment buildings. Here, amidst the dense metropolitan hustle, GVRenting, a local property management company, is pioneering a radical concept that intertwines the ease of apartment living with the benefits of sustainable farming. Their recent initiative, transforming rooftop spaces into productive hydroponic and aquaponic gardens, is reshaping urban life by offering a slice of agrarian paradise amidst the concrete jungle. Sustainable Foundations in Urban Architecture Established during the housing boom of the early 2010s, GVRenting has grown from a modest property management firm into a visionary leader in urban sustainability. The company oversees a portfolio of properties that range from sleek mid-rise residential complexes to towering high-rises, all of which are now doubling as green agricultural sites. These rooftop farms are not mere aesthetic enhancements. They are fully functional agricultural installations that yield an impressive 3-4 tons of fresh vegetables each month. From lush leafy greens to vibrant herbs and nutritious vegetables, the variety is extensive and all are grown organically. The Roots of Innovation: Hydroponics and Aquaponics At the core of GVRenting’s agricultural success are the sophisticated hydroponic and aquaponic systems that utilize advanced technology to cultivate crops in a controlled, soil-free environment. Hydroponics involves growing plants in a nutrient-rich water solution, a method that significantly reduces water usage compared to traditional soil farming. Aquaponics combines this system with aquaculture (fish farming), where the waste produced by fish supplies nutrients for plants, which in return purify the water for the fish. “This closed-loop system is not only resource-efficient but also provides our tenants with the freshest produce possible,” explains Thae An, head of Agricultural Operations at GVRenting. “Our integrated approach ensures that we maximize space and resources while minimizing waste and environmental impact.” A Harvest of Health and Community One of the most visible impacts of GVRenting’s rooftop farms is their role in enhancing the quality of life for tenants. Residents enjoy unlimited access to fresh, organic vegetables, which are distributed weekly through a community-supported agriculture (CSA) model. “The access to fresh produce right from my building’s rooftop has completely transformed my family’s eating habits,” shares Mai Phuong, a resident and mother of two. “We eat healthier, and my children now understand where their food comes from. They see it grow, and they help harvest it—it’s truly a unique urban living experience.” Moreover, these green spaces serve as communal areas where residents can meet, mingle, and bond over gardening activities. They foster a strong sense of community and connectivity among residents, who take pride in their collective effort to maintain and nurture their urban gardens. Economic and Environmental Impact GVRenting’s initiative also presents significant economic benefits. By reducing dependency on external food sources and minimizing food transport, the company is able to lower its overall carbon footprint. Additionally, the rooftop gardens help insulate the buildings, decreasing the need for artificial cooling and thereby reducing energy costs. The environmental benefits are equally impressive. Urban agriculture helps combat the heat island effect common in metropolitan areas, where buildings and roads trap heat, leading to significantly higher temperatures. The plants on the rooftops absorb sunlight, CO2, and heat, helping to moderate the temperature of the buildings and surrounding areas. Looking to the Future Encouraged by the success of their current projects, GVRenting is planning to expand their green initiatives. Future projects include increasing the diversity of crops grown, integrating solar panels to power farm operations, and potentially opening up the gardens to the local community for educational programs. “As we look to the future, our goal is to not only expand our operations but to also inspire other companies and communities to consider similar sustainable practices,” states Vuong Tri Dung, CEO of GVRenting. “We believe that our model of integrating agriculture into urban living can play a crucial role in addressing food security and sustainability challenges in urban environments around the world.” As cities continue to grow and the pressure on rural agricultural areas intensifies, innovative solutions like GVRenting’s urban farms offer a promising path forward. By transforming underutilized spaces into vibrant hubs of productivity and community, GVRenting is paving the way for a more sustainable and food-secure future. Their projects serve as a beacon of innovation, demonstrating that even in the heart of a bustling city, nature can thrive and nourish. Through their commitment to sustainability, community, and innovation, GVRenting is not just reimagining what urban buildings can encapsulate; they are redefining what it means to live in a city. This blend of urban living and agrarian bounty is more than a novelty—it’s a forward-thinking solution to some of the most pressing issues of our time: food security, sustainability, and community cohesion. As GVRenting continues to cultivate these green spaces, they are planting the seeds for a greener, more sustainable future, proving that even the busiest urban environments can be reengineered to contribute positively to the planet and its people. This ambitious project by GVRenting stands as a vibrant testament to the power of innovation and the potential of urban spaces to foster a healthier, more connected, and sustainable way of life. Media contact Brand: GVRenting Contact: Media team Website: https://www.gvrenting.com SOURCE: GVRenting The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More
TIME Interconnect Technology Limited Announces Interim Results For the Six Months Ended 30 June 2024 ACN Newswire

TIME Interconnect Technology Limited Announces Interim Results For the Six Months Ended 30 June 2024

August 30, 2024
HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) TIME Interconnect Technology Limited (“TIME Interconnect”, Stock Code: 1729.HK, with its subsidiaries collectively referred to as the “Group”) is pleased to announce its interim results for the six months ended 30 June 2024 (the “Current Interim Period”).During the Current Interim Period, the pace of economic expansion has been slow, owing to the factors, such as still-high borrowing costs and withdrawal of fiscal support, and the increasing geo-economic fragmentation and geo-politic tension. In spite of these challenges and difficulties, the Group strives to improve its business operations and financial position by proactively seeking potential investment opportunities that would diversify the Group's existing business portfolio, broaden its source of income and enhance value to the shareholders of the company. Benefiting from the AI boom, the revenue of data centre sector and specialty cable sector have significantly increased by 16.6% and 93.6% respectively during the Current Interim Period and the profitability was relatively improved. In addition, the Group paid more attention and efforts in the medical equipment cables business, and with the setup of two new plants, the revenue of medical equipment sector has also significantly increased by 166.0%. At the same time, the Group has completed its investment in two medical and healthcare-related companies in July 2024. The overall profitability of cables and wires has also improved due to these sectors are carrying a better margin. Meanwhile, overseas orders for networking cable sector continued to improve. The revenue of networking cable sector has increased by 25.1% during the Current Interim Period.For the Current Interim Period, the Group recorded revenue amounting to HK$2,666.1 million, represented an increase of HK$39.4 million or 1.5% as compared with HK$2,626.7 million for the six month ended 30 September 2023 (“Previous Interim Period”). Operating profit for the Current Interim Period was HK$309.2 million, represented an increase of HK$74.1 million or 31.5%, as compared with HK$235.1 million for the Previous Interim Period, with the operating profit margin raised from 9.0% to 11.6% for the Current Interim Period. The increase of operating profit was mainly attributable to changes of product mix, higher revenue from medical equipment, data centre and specialty cable sectors with all three market sectors having better profit margin; and lower revenue and profit margin from the server sector.For the Current Interim Period, basic earnings per share was HK10.4 cents, which is 33.3% higher than the basic earnings per share of HK7.8 cents in the Previous Interim Period. The Board Directors of the company is pleased to declare an interim dividend of HK1 cent per share, amounting to a total of approximately HK$19.5 million.Business ReviewThe Group’s turnover by market sector is as follows:Market SectorTurnover (HK$ million)Share of TurnoverSix months ended 30 June 2024Six months ended 30 September 2023ChangesSix months ended 30 June 2024Six months ended 30 September 2023Cable assembly Data centre564.4484.116.6%21.2%18.4% Telecommunication286.5348.6-17.8%10.7%13.3% Medical equipment386.0145.1166.0%14.5%5.5% Industrial equipment21.312.866.4%0.8%0.5% Automotive68.469.5-1.6%2.6%2.7%Digital cable Networking cable614.7491.225.1%23.0%18.7% Specialty cable111.557.693.6%4.2%2.2%Server613.31,017.8-39.7%23.0%38.7%Total2,666.12,626.71.5%100%100%Data centre sectorThe emergence of Al drove the growth and development of the Group's data centre business. During the Current Interim Period, the revenue of data centre sector increased by HK$80.3 million or 16.6% to HK$564.4 million as compared to HK$484.1 million for the Previous Interim Period due to the upgrading of servers and the profitability was relatively improved. Orders from this sector maintained at a high shipment level during the Current Interim Period, and remained the highest revenue sector in the cable assembly business.Telecommunication sectorIt recorded a decrease of revenue from HK$348.6 million for the Previous Interim Period to HK$286.5 million for the Current Interim Period, represented a decrease of HK$62.1 million or 17.8%. The main customers of telecommunication sector are located in PRC, and the main reason for the decline in revenue was the impact of the Lunar New year holidays during the Current Interim Period as compared to the Previous Interim Period.Medical equipment sectorDuring the Current Interim Period, the Group paid more attention and efforts in the medical equipment cables business and continued to enhance its medical equipment customers base, as well as to strengthen its R& D capabilities during the Current Interim Period. Benefited from the setup of two new plants, Time Kunshan and Time Jiangxi, last year and expanded production capacity and R&D capabilities for medical equipment cables products, the revenue of medical equipment sector has significantly increased to HK$386.0 million, represented an increase of HK$240.9 million or 166.0% as compared with HK$145.1 million for the Previous Interim Period.Industrial equipment sectorThe global economy recovered but the pace was slower than expected. The divergences between countries have maintained. High interest rates directly raised the cost of borrowing and constraining economic activity. However, there was slight improvement in the industrial equipment sector. The revenue of industrial equipment sector increased by 66.4% from HK$12.8 million for the Previous Interim Period to HK$21.3 million for the Current Interim Period.Automotive sectorThe revenue of automotive sector was HK$68.4 million for the Current Interim Period, compared with the revenue for the Previous Interim Period of HK$69.5 million, represented a slight decrease of 1.6%. Affected by geopolitics and trading war, the sales orders of automotive wire harness products maintained a lower level during the Current Interim Period. But the Group still believes that the automotive wiring products can help the Group to provide its customers with a broader product portfolio. To capture opportunities brought by the booming electric vehicle market, the Group’s new wholly-owned subsidiary, Linkz Cables Mexico, S. de R.L. de C.V. ("Linkz Mexico"), has been setup in Mexico to increase its market share in markets outside China and Asia.Networking cable sectorEven a lot of negative factors, such as the divergences between countries, wars, high interest rates, strong US dollar and high inflation, were remained exist, overseas orders for networking cable sector continued to improve. The revenue of networking cable for the Current Interim Period was HK$614.7 million, represented an increase of HK$123.5 million or 25.1% as compared with HK$491.2 million for the Previous Interim Period. The rise in copper price indicated that market demand is continuing to improve. The establishment of Linkz Mexico also helps to increase its market share in the U.S. and Mexico markets.Specialty cable sectorSame as data centre sector, Al also stimulated the growth and development of high-speed cables in the specialty cable sector. For the Current Interim Period, the revenue of specialty cable was HK$111.5 million, represented a significant increase of HK$53.9 million or 93.6% as compared with HK$57.6 million for the Previous Interim Period. High-speed cables also carried a better profit margin which benefited to the Group's overall profitability.Server sectorFor the Current Interim Period, the revenue of server was HK$613.3 million, represented a decrease of HK$404.5 million or 39.7% as compared with HK$1,017.8 million for the Previous Interim Period. After a peak of new products shipments at the end of last year, there was a shortage of key components supply this year, resulting in some orders need to be rescheduled.ProspectLooking ahead, on the downside, geopolitical tensions and high interest rates continue to dampen global economic activities. According to the latest forecast of the "World Economic Outlook" issued by the "International Monetary Fund" in 2024, global growth estimated at 3.2 percent in 2023, is projected to continue at the same pace in 2024 and 2025. The latest forecast for global growth five years from now at 3.1 percent is at its lowest in decades. On the upside, inflation could fall faster than expected amid further gains in labor force participation, allowing central banks to bring easing plans forward. Artificial intelligence and stronger structural reforms than anticipated could spur productivity. However, even the Group is facing such challenges and difficulties in the macro-economic environment, the management remains confident in its future business. With the support of Luxshare Group, the Group enjoys advantages in both product manufacturing capabilities and financial strength. The Group will continue to develop strategic businesses and markets, strengthen its business foundation and achieve impressive results during the economic downturn.The Group believes that the PRC’s continued acceleration of 5G technology research and development, as well as the new social normals caused by the epidemic, including work-from-home and online meetings, are expected to drive the demand of cable assembly products and telecommunication sector and benefit the Group’s business growth. In light of this, the management remains confident in 5G-related business.On the other hand, considering the vigorous development of the automotive and electric vehicle markets, the Group believes that the automotive wire harness products can help the Group to provide its customers with a broader product portfolio, and to step in new business sector by enriching the Group's business portfolio and broadening its unique customer base, helping the Group to capture opportunities brought by the booming electric vehicle market. In view of these, the Group has setup a new wholly-owned subsidiary, Linkz Mexico in Mexico to increase its market share in markets outside China and Asia. A new plant is expected to be put into production in the second half of 2024. The new factory will produce digital cables and automotive wire harness products. This is a "China-Plus-One" strategy, which can protect supply chains and export markets against geopolitical tensions and unforeseen disruptions and enable the Group to capture market opportunities upon the arrival of this generation 5G network.Moreover, the utilisation rate of cloud technology in the companies around the world is continuously increasing, which is expected to drive the development of data centre. Meanwhile, the development of 5G will boost the application of big data, IoT, internet gaming and video streaming through cloud platform. To capture the huge market demand, the Group extended its business to server sector, the products offered by the Group under this business are mainly applied in data centres. Having considered that (i) China is actively conducting investment activities to build digital infrastructure; (ii) the PRC manufacturers continue to increase the share of local supply chain due to geopolitics relationship; and (iii) Luxshare Precision has extensive technological knowhow and good customers’ relationships, the Group is optimistic on the potential demand in the market. Meanwhile, the emergence of Al drove the growth and development of the Group's server and data centre sector business. However, geo-economic fragmentation continues to intensify, barriers to the flow of goods, capital and people continue to increase, and supply chain problems continue to arise. All of these have created challenges on the business operations of the Group. The Group will work very hard to find any business solutions to cope with the current economic environment as well as the complex geopolitical relationship around the globe, and continue to expand and consolidate the development of server business.As for the medical equipment sector, the Group expects the demand for medical equipment cables will continue to bring positive impact to the Group’s medical equipment cables orders this year. To catch up with the trend, the Group has established two wholly-owned subsidiaries, Time Kunshan and Time Jiangxi, to expand production capacity and R&D capabilities for medical equipment cables products.Moreover, the Group completed the investment in two medical and health related companies in July 2024. One is Cosmic M.E. Inc. (“CME”), which has become a subsidiary of the Company following its share subscription. With a proven operating history of over 30 years, CME is engaged in the developing, manufacturing and selling of electronic medical instruments and other medical equipment and devices. The Group believes that the subscription will allow it to leverage on CME's extensive knowhow and existing production facilities to immediately deliver reliable and high quality medical products to its existing and new customers. It will certainly bring synergy to both parties for the development of medical related products in terms of R&D, manufacturing capabilities and global market expansion. Another one is Valkyrie Industries Limited ("Valkyrie"), the company entitled shareholding 16.75% by share subscription. Valkyrie is a UK based startup with 7 years' long professional experience in haptics and virtual reality. It has developed haptic technology with patents, which can create weight, resistance and assistive forces for users in virtual simulations. It combines fitness, wellness and gaming for optimising human performance for the huge markets of games and neuromuscular recovery. The Group considered that the Valkyrie's technology will be a good opportunity for the Group to extend its product mix offered to the existing major customer and also tap into the new business sector so as to diversify the Group's business portfolio and broaden its income stream with distinct customer base. Besides, a new liaison office, Time Interconnect America Inc., has been established in San Diego since July 2024 to seize more business opportunities in medical-related markets. Moving ahead, the Group believes that this sector will maintain its dynamic pace of growth, considering the arising demand from the medical equipment market. The Group will pay more attention and efforts in this sector and continue to enhance its medical equipment customers base, as well as to strengthen its R&D capabilities.Riding on the PRC government's policy of "Channelling Computing Resources from the Eastern Areas to the Western Regions", Luxshare Precision will deploy the platform advantages and market position of the Luxshare Group and introduce strategic resources to the Company with intention to further strengthen the Company's potential for continuous growth and core competitiveness in its market and to enable the Company to develop strategically to become an all-rounded network solutions and infrastructure provider, so as to create greater value for the shareholders. In this regard, Luxshare Precision is conducting a strategic review of the operations and financial position of the Company, and actively exploring business opportunities for the growth and development, in both organic and inorganic manners, for the Company. The Company believes that, with the support of Luxshare Precision, the Group will create more and more possibilities in the future.– End –About TIME Interconnect Technology LimitedTIME Interconnect Technology Limited is a well-established supplier of customised interconnect solutions with over 30 years’ experience in the industry. The Group is headquartered in Hong Kong, and has manufacturing facilities in Shanghai, Suzhou, Jiangxi and Huizhou, the People’s Republic of China (“PRC”), Japan and Mexico. The Group currently manufactures and supplies a wide variety of copper & optical fiber cable assemblies, digital cable products, medical products and servers which are produced to the specifications and designs of its individual customer partners. Its products are used by a number of established PRC and international customers in a variety of market sectors, including telecommunication, data centre, industrial equipment, medical equipment, automotive wire harness, digital cables and server.This press release is disseminated by Bright Communications International Limited on behalf of TIME Interconnect Technology Limited. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

天津银行召开2024年中期业绩发布会

August 30, 2024
香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 8月29日，天津银行召开2024年中期业绩发布会。2024年上半年，天津银行扎实做好金融「五篇大文章」，赋能「新质生产力」，积极践行「四个善作善成」重要要求，聚焦「科技创新、产业焕新、城市更新」「盘活存量、培育增量、提升质量」和天津市「十项行动」，深化法人治理，扎实推进「双五战役」，实现平稳开局，稳中有进，为全年稳健发展奠定良好基础。业务经营形势进一步向好，高质量发展基础进一步夯实经营规模持续增长。资产总额人民币8,973.8亿元，较上年末增长6.7%，其中贷款余额人民币4,414.0亿元，较上年末增长11.5%。负债总额人民币8,304.6亿元，较上年末增长7.1%，其中存款余额人民币4,822.2亿元，较上年末增长7.0%。收入利润实现双增。实现营业收入人民币87.6亿元，同比增长7.7%；实现拨备前利润人民币67.4亿元，同比增长8.1%；实现凈利润人民币19.8亿元，每股收益人民币0.32元。资产质量有效改善。不良贷款率1.54%，较上年末下降0.16个百分点；拨备覆盖率181.75%，较上年末上升13.89个百分点，风险抵补能力不断增强。重点着墨「五篇大文章」报告期内，天津银行已制定「关于做好金融五篇大文章赋能天津高质量发展的实施方案」，协同推进金融「五篇大文章」。搭建科技金融服务体系。作为「科技-产业-金融」新循环试点行，优化科技金融服务模式，整合科技金融产品服务体系，发布「智慧科技通」金融服务方案。科技创新企业贷款余额人民币144.94亿元，较上年末增长24.0%；承销及投资科创票据人民币48.5亿元；打造天津银行系列科创成长基金，推广「一区一基金」模式，三只基金的合作协议已签署落地。推动绿色金融高质量发展。绿色贷款余额人民币330.41亿元，较上年末增长35.69%，发放天津市首笔「企业绿码」挂钩贷款、天津银行首笔EOD模式项目贷款和首笔可持续发展挂钩跨境银团贷款。实现ESG领域债券承销及投资人民币81.11亿元，在交易商协会2024年上半年绿色债务融资工具投资人排行榜中位列城商行第三位。普惠金融向深向实发展。强化金融科技赋能，丰富产品服务体系，稳步提升普惠金融服务效率和水平。涉农贷款余额人民币264.27亿元，较上年末增长23.55%，「智慧富民通」累计放款人民币40.77亿元，惠及6.53万农户。打造「智慧通普惠」数字金融生态服务平台，聚焦小微企业、个体工商户，智慧商户通合作商户120.53万户，较上年末增长21.65%；「智慧商户通·天行用呗」累计放款人民币294.01亿元，较上年末增长49.88%，从源头上解决了个体工商户「融资难、融资慢、融资贵」的难题。打造「金秋港湾」养老金融特色品牌。推出养老金融「专有投资者教育、专属产品货架、有温度的专业服务、专项满意度调研、专注打造特色网点、专策金融支持」「六专」服务体系，营业网点进一步对标适老服务标准，优化适老金融线上服务渠道，举办天津市养老金融暨银发经济专题研讨交流活动。适老储蓄产品余额人民币848.52亿元，较上年末增长8.64%；适老理财产品余额人民币262.01亿元，较上年末增长6.71%；第三代社保卡新增激活8.7万张，网均发卡数量位列天津市第一。深化数字金融助力新质生产力。强化顶层设计，积极践行数字银行建设战略，对外聚焦「服务效能」，对内聚焦「安全生产」，不断提升一体化运营、多元化数据价值释放、智慧化服务再造、数智化营销、综合化事务支撑及智能化风控等能力。培育数字经营新模式，开启企业级全渠道客户数字化运营平台，通过大数据模型实现获客、活客和价值转化能力显著增强，截至报告期末，实际触达基础客户324.65万户，带动手机银行新增客户11.35万户，AUM月日均提升人民币37.60亿元。激发数字金融服务新动能，推出全员作战系统，为战略部署高效执行和职能部门协同作战打造新引擎；通过「数看天行」全面展现经营数据，提升拓客和经营决策效能。加速科技成果积淀转化，年内荣获鑫智奖「数智化转型先锋 企业」等奖项5项，获批17项知识产权。深入践行「四个善作善成」重要要求在发展新质生产力上善作善成。发布「聚力新质生产力发展的工作方案」，旨在以金融力量支持新质生产力加快发展。支持现代产业体系，中长期制造业贷款余额人民币145.28亿元，较上年末增长36.23%，12条重点产业链贷款余额人民币30.69亿元，较上年末增长33.46%。供应链贷款余额人民币126.95亿元，较上年末增长14%，天津地区绿色贷款余额人民币256.01亿元，较上年末增长56.43%。支持科技创新和产业转化，运用「股、债、贷、基、租、保」多元化接力式的综合金融服务，加大对天开高教科创园企业和人才的精准支持。支持盘活用好存量资源，累计为天津市资产盘活领域投放信贷资金人民币385亿元。在全面深化改革开放上善作善成。支持建设高水平开放型经济新体制，聚焦港产城融合发展行动，为滨海新区高质量发展、北方国际航运核心区、「一带一路」提供金融支持。滨海新区对公贷款投放余额人民币511.66亿元，较上年末增长17.54%；支持京津冀协同发展，京津冀地区贷款余额人民币3,405.1亿元，较上年末增长16.4%；累计承销及投资京津冀地区各类债券人民币476.59亿元。与武清区、津南区政府及京津冀16家企业签署战略合作协议，「京津冀产业交流综合金融服务平台」发布上线。在推动文化传承发展上善作善成。支持科教兴市人才强市行动，强化金融与教育领域深度融合，提供贷款融资、智慧校园建设等综合金融服务。打造「运动金融」品牌，发放马拉松主题「悦动卡」和专属理财，理财募集资金已达人民币7.4亿元；「智慧文旅通」「智慧商户通」助力文旅场景拓展，盘活抵羊、利顺德等「老字号、老品牌」，通过商标权、专利权质押的方式为老字号企业提供新增贷款人民币7.4亿元。与佛罗伦萨小镇商圈签署战略合作协议，构建京津冀区域商旅文体农融合特色消费生态圈。将古文化街建设成为天津市「优化支付服务」标杆场景。在提升城市治理现代化水平上善作善成。助力城市更新，制定《支持「中心城区更新提升行动」服务方案》，在城市更新领域提供授信支持人民币37.3亿元。搭建智慧公共服务体系，建设智慧教育通、智慧医疗通，提供全方位的综合性数字化服务方案，推动城市业态、功能、品质不断提升。下一步，天津银行将继续深入贯彻党的二十大、二十届三中全会及中央金融工作会议精神，做好「五篇大文章」，深入践行「四个善作善成」，落实天津市委市政府「三量」「三新」工作要求，服务天津市「十项行动」，为高质量发展注入推动力支撑力。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
Fujitsu establishes Open All-Photonics Network Lab in Europe to promote global expansion of innovative network infrastructure JCN Newswire

Fujitsu establishes Open All-Photonics Network Lab in Europe to promote global expansion of innovative network infrastructure

August 30, 2024
KAWASAKI, Japan, Aug 30, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced plans to establish an Open All-Photonics Network (APN) (1) Lab in Düsseldorf, Germany from November 2024 to March 2025. The aim is to popularize APNs and promote the global expansion of the Innovative Optical and Wireless Network (IOWN) (2). The lab is the first of its kind outside of Japan (3).Figure 1: Fujitsu Technology Solutions GmbH in Düsseldorf, GermanyVisitors will be able to experience firsthand the benefits of Open APN technology, including its ease of operation and versatility. Network carriers, data center operators and vendors will be able to use the lab to verify APN functionality and multi-vendor connectivity.Open APNs facilitate the connection of multi-vendor products and solutions while also providing high capacity, low latency and low power consumption. A new IOWN service is planned to be introduced in Japan from fiscal 2025, and it is expected that APNs will become more widespread.Fujitsu has been working towards the open sourcing of network technologies, including mobile networks. With the establishment of the Open APN Lab, the company will continue to promote the understanding of open APN technology and encourage the wider use of this low-power, high-capacity technology as part of its commitment to creating a sustainable society.BackgroundAs AI, big data processing, and 5G, become more widespread globally, there is a growing need for larger optical data transmission capacities between wireless base stations and core networks, as well as data centers. In addition, with the expansion of telecommunication infrastructure, network carriers and data center operators are prioritizing efforts to reduce power consumption, especially in Europe where energy costs are soaring.Düsseldorf is home to many telecom-related companies. The Open APN Lab will be located within easy access of Düsseldorf International Airport and major European cities, making it convenient for visits by network carriers both in Germany and elsewhere in Europe.The lab will allow companies to experience using APNs developed by Fujitsu and experience firsthand the benefits they offer as well as gain information about future network services through introductions of APN use cases.The establishment of this Open APN Lab comes as part of a contract gained from the Ministry of Internal Affairs and Communications (MIC)to conduct field trials towards the overseas deployment of APNs in Europe.Future PlansAfter the lab closes in March 2025, Fujitsu will conduct field trials. The company also plans to further expand its APN labs globally, including in North America.[1] All-Photonics Network (APN) :A network that achieves ultra-high speed, low latency, and low power consumption by transmitting optical signals without optical-electrical conversion[2] IOWN (Innovative Optical and Wireless Network) :An innovative network and information processing infrastructure capable of providing high-speed, large-capacity communications and vast computing resources by utilizing advanced technologies such as photoelectric fusion[3] The world's first facility :According to research by Fujitsu as of August 30, 2024About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press Contacts:Fujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.
More

Fosun Pursues Solid Business Development with Predictable Profit

August 30, 2024
HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - On 28 August 2024, Fosun International (HKEX: 0656) announced its 2024 interim results. During the reporting period, its revenue continued to grow, reaching RMB97.84 billion. Industrial operation profit maintained growth, reaching RMB3.47 billion, and profit attributable to owners of the parent was RMB720 million.Guo Guangchang, Chairman of Fosun International, said at the results presentation on the morning of 29 August, “In the first half of the year, although the macro environment remained challenging, we resolutely executed our strategy of focusing on core businesses, developing industry-leading companies and products in the industries where we have formed advantages. Such strategy has been proven effective in general. Looking ahead, we will remain focus on innovation and globalization, while focusing on asset-light operations, driving long-term development with competitive core strengths.”Since the beginning of 2024, the domestic economic recovery has been rocky and the international market has remained volatile, which has brought challenges to Chinese companies including Fosun. Fosun steadfastly pushed forward its strategic focus, driving development with core strengths, achieving quality and efficiency improvement in core industries, and maintaining a solid asset base.Analysts believe that, based on Fosun’s interim results, Fosun’s focus on the core industries in the household consumption sector and its proactive approach to driving innovation and globalization have further reinforced its business foundation, resulting in predictable stable profits. Additionally, over the past two years, Fosun has actively pursued asset-light operations, optimized asset portfolio, and continued to reduce leverage. These efforts have resulted in abundant cash reserves and a stronger financial cushion, which are expected to prompt the market to reassess Fosun’s value.Staying ahead in globalization and innovation, reinforcing business foundation to develop industry-leading companies and products In the first half of the year, Fosun’s four core subsidiaries, namely Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group (“FTG”), achieved total revenue of RMB72.17 billion, accounting for 74% of the Group’s total revenue. Fosun’s strategy of focusing on core businesses has shown increasing benefits, with its advantages in core industries such as pharmaceuticals, tourism, consumption, and insurance continue to be strengthened.With years of effort in the aforementioned sectors, Fosun has developed a number of industry-leading companies and products.For example, in the first half of this year, Fosun Pharma, which ranks second among the top 100 pharmaceutical companies in China, was selected as one of top 20 global pharmaceutical companies in terms of pipeline scale for the third consecutive year. Shanghai Henlius is the first Chinese profitable innovative biopharmaceutical company listed in Hong Kong, with multiple independently developed monoclonal antibody biosimilars that are driving the rapid development of China’s biopharmaceutical industry. Its first blockbuster product, HANLIKANG, is the first domestic biosimilar approved for marketing. Fosun Insurance Portugal holds the largest market share in the Portuguese insurance market and ranks among the leaders in the insurance sector across Portuguese-speaking regions globally. Easun Technology, in the intelligent manufacturing segment, is a global leading automation and digitalization company.In addition, in the Happiness business segment, Club Med, a subsidiary of FTG, is the global leader that offers exquisite “all-inclusive” holidays. Atlantis Sanya is the leading integrated high-end tourism destination in China, helping to usher Hainan tourism into the 3.0 era. Laomiao Gold, a subsidiary of Yuyuan, is a China time-honored brand and a nationally renowned jewelry brand. These industry-leading companies and products have helped Fosun consolidate its leading position in related sectors.For Fosun, steady and profitable growth is driven by two factors: innovation and globalization.Amid the current domestic economic “involution”, “going global” has become a “must-do” for businesses. Fosun, which began its globalization journey as early as 2007, has become one of the benchmark global companies rooted in China. It has also established a profound industrial presence in more than 35 countries and regions worldwide.During its 17-year globalization journey, Fosun has achieved many successful projects and faced various challenges. Most importantly, this experience has allowed Fosun to develop globalization capabilities that rare among domestic companies. In addition, it has allowed Fosun to connect different markets, industries, and resources globally, achieving global presence, operations and development, while continuously enhancing its global operation capabilities.This is further illustrated by the following data, the Group’s overseas revenue for the first half of 2024 reached RMB45.87 billion, representing a year-on-year increase of 4%, and accounting for 47% of total revenue. Nearly half of the revenue came from overseas, which is rare among Chinese companies.More importantly, Fosun has actively driven the empowerment and synergy of its corporate ecosystem in the course of globalization. Its domestic and overseas member companies have made significant progress in global research and development (R&D), business expansion, operations, and investment and financing.For example, HANQUYOU, independently developed by Fosun’s subsidiary Shanghai Henlius, received marketing approval from the United States (U.S.) Food and Drug Administration (FDA), making it a “Chinese” monoclonal antibody biosimilar approved in China, the European Union (EU), and the U.S. HANLIKANG, China’s first biosimilar, received marketing approval from the Peruvian General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru, making it the third self-developed drug of Shanghai Henlius to be approved for overseas marketing after HANQUYOU and HANSIZHUANG.Moreover, Club Med, a subsidiary of FTG that operates 67 resorts worldwide, achieved a record-high business volume of RMB8.89 billion in the first half of 2024, representing a year-on-year increase of 10.3%. Club Med’s business in the Europe, Middle East and Africa (EMEA) region and the Americas continued to grow, and its business in Asia-Pacific region recovered significantly. In May 2024, Club Med signed an agreement in Oman for the launch of its first resort in the Middle East.Fosun Insurance Portugal, which began its operations in Portugal, has been actively expanding into overseas markets. In the first half of 2024, it achieved business growth domestically and internationally. The contribution from overseas markets further increased, with international business recording premiums of EUR885 million, accounting for over 30% of the total premiums; the net profit of international business was approximately EUR51 million, accounting for over 40%.Easun Technology, a global leading automation and digitalization company under Fosun, has also been advancing its overseas expansion. In the first half of 2024, it achieved new overseas orders of RMB3.99 billion, with a significant increase in orders from the U.S. market, reaching RMB750 million, more than doubling year-on-year.Innovation is also a core competence that Fosun has accumulated over a long period of time and has always adhered to. During the reporting period, Fosun invested a total of RMB3.5 billion to deepen its technological and innovation capabilities. Its integrated innovation model under a global vision has become more mature, resulting in a number of ground-breaking achievements that are steadily generating profits and driving Fosun’s growth.In terms of innovative drug R&D, Fosun Pharma has 4 products with a total of 9 indications were approved for marketing; 4 products with a total of 9 indications had entered the pre-launch approval stage/key clinical stage; and 9 products (by indication) have been approved to conduct clinical trials. Shanghai Henlius’ independently developed and manufactured innovative biologics continue to make breakthroughs. The world’s first anti-PD-1 monoclonal antibody for the first-line treatment of small cell lung cancer (SCLC), HANSIZHUANG, has been approved for 4 indications, benefiting over 75,000 patients. It has also been out-licensed to over 70 countries and regions, including the U.S., Europe, Southeast Asia, the Middle East, and North Africa. In addition, the new indication for SUKEXIN, a new generation of oral thrombopoietin receptor agonist (TPO-RA), has been approved by the National Medical Products Administration (NMPA).New progress has also been made in the deployment of cutting-edge medical devices and innovative therapies. In June 2024, Intuitive Fosun Headquarters Industrial Base was inaugurated in Shanghai. It is the largest integrated R&D, production and training base of Intuitive Surgical in the Asia-Pacific region, significantly accelerating the localization of the da Vinci surgical robot. Intuitive Fosun’s Ion robotic bronchoscopy was approved by the NMPA in March this year and was launched in July 2024.“Asset-light operations” taking shape, poised for revaluationBenefitting from the strong support in its business operations, Fosun’s financials have also continued to improve. During the reporting period, Fosun continuously optimized its asset portfolio, continuously reduced leverage, and maintained a sound financial position. As of 30 June 2024, the Group’s adjusted total debt-to-capital ratio was 50.2%, maintaining a downward trend since 2020. Adjusted NAV was HK$17.4 per share, indicating that Fosun International’s current share price is significantly undervalued.Meanwhile, Fosun has actively strengthened its financial cushion and maintained ample cash reserves. As of 30 June 2024, Fosun International’s cash and bank balances and term deposits reached RMB109.55 billion, representing an increase of RMB17.1 billion compared to the end of 2023. In the 17 years since its listing, Fosun has accumulatively paid out HK$25.6 billion in dividends, with the dividend payout ratio gradually increasing to over 20% in the past five years.In June 2024, the international rating agency S&P fully recognized the effectiveness of Fosun’s financial strategy and affirmed its rating outlook as “stable”.While achieving stable profits through ongoing innovation and globalization, Fosun has also responded to the new market environment by streamlining its business. It has progressively exited some non-core industries and has actively advanced its asset-light strategy, which is now taking shape.In May 2024, Fosun sold all of its 99.74% stake in the German private bank HAL, which attracted market attention. After the completion of the transaction, Fosun will no longer hold any shares in HAL, but will retain the HAFS asset servicing business, managing approximately EUR100 billion in assets in an asset-light operation model.In the tourism sector, Fosun’s asset-light operation model has achieved remarkable results, with IPs such as Club Med, Atlantis Sanya, and Taicang Alps becoming benchmarks in the domestic tourism industry. In the first half of 2024, 85% of Club Med resorts adopted a leasing and management model, with the proportion of self-owned resorts declining to 15%.In April 2024, the AMAZE Snow Mountain Camp, FTG’s new IP in Lijiang Club Med Resort, quickly became a hit after its opening, driving significant occupancy increases at the nearby Club Med Lijiang Resort and Joy Holiday Hotel Lijiang.In June 2024, FTG joined hands with the Taicang Municipal Government to build the phase II of Taicang Alps Resort, a one-stop ice and snow-themed urban tourist destination. The phase II project, with a total investment of over RMB5 billion, is funded by the Taicang Municipal Government and operated and managed by FTG. The successful operation of the Alps Snow Live has provided confidence and momentum for the phase II project, which is expected to set several world records in ski resorts.Fosun has also joined hands with partners to set up a number of industry funds to drive the future of advantageous industries. In March 2024, leveraging its leading advantages in biomedicine, Fosun Pharma joined hands with Shenzhen Guidance Fund and seven other investors to jointly establish a RMB5.0 billion biomedical industry fund, with all proceeds to be invested in biomedical, cells, genes, etc. Shanghai Fujian Equity Investment Fund Management, a subsidiary of Fosun Pharma, was selected through public selection process in Shenzhen to exclusively manage this fund. In April this year, the Shenzhen Municipal Government and Fosun signed a strategic cooperation framework agreement, both parties will further strengthen cooperation in areas such as biomedicine, cultural and sports tourism, and fashionable consumption.In addition, Fosun Capital, together with Wuhan Innovation Investment and Wuhan Fund, established a RMB3.0 billion industry fund with an initial scale of RMB1.1 billion in April 2024. This is the first batch of market-oriented fund invested by Hubei Province since the establishment of the RMB20.0 billion government guidance fund, mainly focusing on the four major sectors of new generation information technology, dual carbon, intelligent manufacturing, and consumption.Given the current market environment, it is expected that Fosun will continue to focus on asset-light operations, continuously expand its “circle of friends”, strengthen in-depth cooperation with all parties, and achieve win-win results through complementing each other’s advantages.Market analysts believe that Fosun has achieved sustained and stable profits leveraging its core strategies of innovation and globalization. In addition, by exiting non-core assets, pursuing asset-light operations, and continuously reducing debt, Fosun has maintained robust financial health, paving the way for a potential market revaluation.Guo Guangchang believes that in the future, investors will place greater emphasis on the growth of core industries and the stability of cash flow. “One-off asset sales are only short-term solutions. The growth of core businesses is crucial for a company to achieve stable profits.” Fosun aims to build a consumer group centered on core industries, ensuring more predictable business development and profits. At both the group level and within each business unit, Fosun is committed to creating value for its customers and investors that is manageable in terms of risk and promotes steady growth. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Rockbird Media Triumphs with Inaugural Vietnam Edition of the Retail and E-Commerce Summit Asia ACN Newswire

Rockbird Media Triumphs with Inaugural Vietnam Edition of the Retail and E-Commerce Summit Asia

August 30, 2024
HO CHI MINH CITY, VIETNAM, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - The much-anticipated Retail & E-Commerce Summit Asia (RESA) 2024 made history as it concluded its inaugural event in Vietnam, following its remarkable success across other countries in Southeast Asia. Held on August 22, 2024, at Mai House, Ho Chi Minh City, this landmark summit welcomed retail and e-commerce leaders seeking to capitalize on digital expansion.Attendees, including C-level executives, industry innovators, and emerging entrepreneurs, engaged in a day of transformative discussions and networking opportunities that set the stage for the future of digital retail growth.With the theme "Retail Revolution: Solidifying Growth Through Digital Expansion," the event offered unparalleled insights into the dynamic intersection of retail and technology in burgeoning markets such as Vietnam. Participants gained access to cutting-edge strategies and exclusive content aimed at navigating the complexities of today’s e-commerce landscape, ensuring they were left equipped with actionable knowledge and essential connections.On the valuable insights from the first-ever RESA Vietnam, it’s all about personalization for Le Huynh Phuong Thuc, Managing Director of Guardian Vietnam and one of the event speakers. “The more personalization that we can have, the more we understand about the customer and have the customized offers to the customers at the right timing, with the right value, with the right products.”With Vietnam's market experiencing robust growth, fueled by the potential of digital expansion and increasing foreign investment in retail and e-commerce, RESA offered a prime opportunity to enhance industry knowledge and network. The summit's unique format fostered a collaborative environment where industry leaders could exchange ideas and explore future opportunities.“Given this is the first time that you organized an event here, I say it's impressive,” Huyen Trinh-Thanh, Co-Founder and CGO of Piktina, and another speaker, noted of the event. “I enjoyed the quality of the discussions today. I've got to meet a lot of good people as well as C-suite or C-level people, all of the decision-makers are in the room. The discussions were thoughtful and insightful.”For more information, you can visit: https://rockbirdmedia.comAbout rockbird mediaRockbird media is an international business media company that produces B2B events and offers business solutions.Whether it is through online media and content, must-have business intelligence and analytics, effective networking, and partnering solutions, we help businesses and professionals learn more about the latest trends, and know more about their customers, peers, and competition, to make that decision that allows them to grow.Media contact:annjubelle@rockbirdmedia.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More

光大环境：稳健增长与绿色担当并重，引领行业可持续发展

August 30, 2024
香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 近日，中国光大环境（集团）有限公司（257.HK）（下称“光大环境”或“公司”）公布了2024中期业绩。作为一站式、全方位的环境综合治理服务商，光大环境不仅保持业务稳健增长，更在环境保护和社会责任方面发挥重要作用，引领行业标杆。绿色科创赋能未来 广泛推动绿色合作光大环境积极参与高层行业对话和国际论坛，推动区域环境合作。2024年上半年，公司管理层先后出席了美丽中国百人论坛2024年会、上海合作组织国家绿色发展论坛。在上海合作组织国家绿色发展论坛上，光大环境与各国代表共同探讨绿色发展战略，为全球绿色发展贡献中国方案。论坛期间，光大环境总裁栾祖盛参与了“产业集聚共建繁荣上合”主题环节，并以《发展绿色生产力 共建可持续未来》为题发言，重点分享了开展务实科技交流，构建绿色创新生态圈；推动低碳产能合作，打造绿色产业聚集区；加快标志项目落地，树立绿色上合新标杆三方面的思考。此外，公司作为参建单位受邀还出席了海南博鳌近零碳示范区运行启动会。今年上半年，公司旗下越南顺化垃圾发电项目竣工仪式获越南国家政府总理出席，同时，公司亦受邀出席越南总理与在越中资企业的座谈会，展示了中国企业在“一带一路”倡议下的担当和影响力。公开透明沟通 提升市场形象秉持开放透明的原则，光大环境主动接受各界监督，展现了高度的企业责任感和治理水平。2024年上半年，公司组织了近20次项目考察活动，吸引逾百家境内外投资机构参加。这些考察活动涵盖了公司在垃圾发电、水环境治理、生物质能利用等多个领域的代表性项目，让投资者、分析师和媒体代表深入了解了光大环境的运营模式、技术创新和发展战略。通过面对面交流和实地考察，公司深化了与各利益相关方的沟通，增进了相互理解和信任。这种开放、透明的沟通策略不仅提升了公司的市场形象，也为吸引更多投资者和合作伙伴奠定了坚实基础。截至2024年6月30日，已有23家机构给予光大环境正面评级，公司股价较2023年底升逾50%。倡导环保低碳 携手各界筑绿光大环境积极推动环保宣传，致力于提升公众的环保意识和参与度。在内地，公司围绕“世界水日”、“世界环境日”等重要环保主题日，在全国各地的项目公司组织开展了形式多样、内容丰富的环保活动。在日常亦通过策划并组织主题形式多样的公益活动，深入当地社区，与民众互利共融，吸引了大量市民参与，有效普及了环保知识，培养了公众的环保习惯。截至2024年6月30日，光大环境累计有220个项目向公众开放，线下接待境内外各界参观考察人士约9,500人次，参与和观看线上活动的人数约8万人次。获颁多项荣誉，巩固行业影响力2024年上半年，光大环境凭借卓越的经营业绩和社会贡献，收获多项荣誉。公司连续13年位居中国“年度固废十大影响力企业”榜首，获标普第七次纳入《可持续发展年鉴》；旗下光大水务连续7年入选“中国水业十大影响力企业”榜单；光大绿色环保更是第3次获评《亚洲周刊》全球卓越ESG大奖。这些荣誉和成就进一步巩固了光大环境在环保领域的领军地位，为公司未来的发展注入了强劲动力。面对国家“双碳”目标和对照中国式现代化建设目标要求，作为行业领军企业，光大环境在推动绿色低碳发展、改善生态环境质量、促进经济社会可持续发展等方面发挥了重要作用。公司管理层表示，未来，光大环境将继续秉持“创造更好投资价值，承担更多社会责任”的企业使命，坚持创新驱动，深化国际合作，不断提升环境治理能力和水平，为中国生态文明建设和全球可持续发展贡献更大力量。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More

渤海银行公布2024年中期业绩

August 30, 2024
香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 渤海银行股份有限公司（「渤海银行」或「公司」；股份代号：9668.HK）宣布公司及其附属公司（「集团」）截至2024年6月30日止六个月（「报告期」）之未经审计综合中期业绩。2024年上半年，国际环境更趋复杂严峻，主要经济体经济增长与货币政策有所分化。中国经济运行延续回升向好态势，高质量发展扎实推进，但仍面临有效需求不足、企业经营压力较大、重点领域风险隐患较多等困难。集团全面落实监管政策要求，坚持稳中求进工作总基调，以进促稳，先立后破，持续推进「十个专项工作」攻坚，扎实落地高质量发展方案各项目标任务，优化业务布局，狠抓科技创新，突出转型驱动，强化风险防控，在转方式、调结构、提质量、增效益上积极进取，推动高质量发展取得新成效。报告期内，集团实现营业收入131.45亿元，净利润36.97亿元，总体保持了平稳发展态势。截至报告期末，资产总额17,479.96亿元，较上年末新增152.62亿元，增幅0.88%。其中，发放贷款和垫款总额（未含应计利息）为9,478.52亿元，较上年末新增152.08亿元，增幅1.63%；负债总额16,294.25亿元，较上年末新增110.94亿元，增幅0.69%。其中，吸收存款总额（未含应计利息）9,346.22亿元，较上年末新增194.60亿元，增幅2.13%；不良贷款余额为171.12亿元，比上年末增加5.54亿元；不良贷款率为1.81%，比上年末上升0.03个百分点。贷款损失准备计提充足，贷款减值准备271.07亿元，比上年末增加11.20亿元。贷款拨备率2.86%，拨备覆盖率158.41%，均符合监管要求。回归服务实体经济本源 扎实推进公司银行业务高质量转型报告期内，公司银行以服务国家战略目标和实体经济为根本宗旨，紧紧围绕做好科技金融、绿色金融、普惠金融、养老金融、数字金融五篇大文章，坚持行业银行、交易银行、轻型银行定位，优化业务结构，提升经营水平，扎实推进公司银行业务高质量转型发展。客户建设方面，报告期内，公司银行坚持以客户为中心，持续完善行业战略客群、基础专项客群、政府机构客群、区域重点客群等四大对公客群服务体系。截至报告期末，公司银行全量客户合计111,472户，比上年末增加6,040户，增长5.73%。负债业务方面，公司银行始终坚持「存款为本」的理念，通过传统及非传统信贷产品组合应用，搭建业务场景，为客户提供综合金融服务，积极拓展低成本存款。同时，推进数字化系统建设，完善产品功能，提升服务水平，优化客户体验，推动存款规模增长和存款结构优化。截至报告期末，公司存款总额5,942.76亿元，比上年末增加281.09亿元，增长4.96%。资产业务方面，公司银行围绕服务实体经济，持续加大对科技金融、制造业、绿色信贷、乡村振兴等重点领域的支持力度。制造业、科创类小微企业、绿色金融、涉农等重点领域贷款增速均大幅高于一般性贷款增速。截至报告期末，公司贷款总额6,366.66亿元，比上年末增加699.26亿元，增长12.34%。科技企业贷款余额438.95亿元，其中专精特新企业贷款余额同比增长23.03%，高技术产业贷款余额同比增长22.08%，知识产权密集型产业贷款余额同比增长12.79%；制造业贷款余额912.79亿元，较上年末增长6.84%；绿色贷款余额377.45亿元，较上年末增长20.75%；涉农贷款余额419.16亿元，较上年末增长15.62%。交易银行业务方面，交易银行持续加强产品化、场景化、线上化建设，围绕供应链金融、票据服务、现金管理解决方案、国际结算与贸易融资，构筑交易银行业务生态，深挖客户需求，为客户提供一站式服务体验。报告期内，交易银行实现非息收入9.60亿元，同比增长5.73%。其中，价差收入1.43亿元，同比增长268.98%。交易银行业务表内外资产规模4,707.4亿元， 同比增长14.17%；累计投放4,347.77亿元，同比增长78.23%。全行线上公司业务客户数13,286户，新一代票据业务活跃客户数2,109户。实现国内信用证及福费廷业务投放1,163.61亿元。海纳池累计投放金额124.19亿元，在池资产规模156.54亿元。投资银行业务方面，集团坚定FPA经营发展转型方向，着力打造流量银行，盘活存量、用好增量、做大流量，以具有比较优势的钩子产品作为业务破局点，将服务经济融资总量作为工作的出发点和落脚点，持续优化业务结构、丰富收入来源、发力渠道拓展、夯实客户基础，强化通过债券承销、交易撮合、资产流转、理财子公司对接等高效利用资本方式实现拓展客户、沉淀存款、提升效益的能力。2024年上半年，投资银行债券主承销业务规模913.56亿元，同比增长105.48%；累计承销各类创新债券（含结构化融资产品）31只，承销金额合计120.17亿元。交易撮合业务稳步发展，报告期内，撮合对接资产规模433.25亿元，同比增长5.78%。资产托管业务方面，报告期内，资产托管业务扎实履行服务实体经济高质量发展职能，坚持专业化、规范化发展，持续优化运营流程，夯实客户基础，探索创新服务模式，推动托管规模快速提升。截至报告期末，资产托管及外包业务规模余额28,058.55亿元；报告期内，实现资产托管及外包业务收入15,417.77万元。根据中国银行业协会2024年第二季度统计数据，集团托管规模排名第20位。普惠金融业务方面，报告期内，集团重点聚焦普惠金融产品谱系打造，着力构建「链系列、数系列、快系列、科系列」四大普惠金融产品谱系，实现线上线下相结合，大幅提升服务效率和客户体验，打造具有渤海特色的普惠服务品牌。截至报告期末，集团普惠贷款余额457.35亿元；普惠贷款客户数87,402户；当年累放贷款执行利率4.4%。着力打造账户银行、财富银行、生态银行 零售银行业务稳步发展报告期内，零售银行着力打造账户银行、财富银行、生态银行，推进「账户+支付+金融产品」的综合服务体系建设，强化生态拓客模式，依托技术支撑和数字驱动，深化客户分层分群经营，以客户视角聚合产品服务，优化产品谱系，改善业务结构，推进零售业务稳步发展。截至报告期末，集团零售存款余额2,103.19亿元，较上年末增加93.17亿元。客户发展方面，集团加快数字化运营能力突破，聚焦多元渠道建设、拓客模式转型和生态场景搭建，完善客户分层分群经营服务策略，优化代发和支付服务工具，促进零售客户增量提质。截至报告期末，集团零售客户总量793.18万户，较年初净增21.93万户。资产业务方面，报告期内，零售资产业务以国家信贷政策为导向，加快推进业务高质量转型发展，坚持以客户为中心，满足客户多样化信贷需求。截至报告期末，个人贷款余额2,247.65亿元。财富管理方面，持续打造「渤银E财」产品货架，提升产品供应能力。报告期内，零售财富资产规模稳步提升，同比增长407.24%，其中代销理财存量规模增速较上年同期提升26.25个百分点，代销信托存量规模同比增长116.14%，发展势头良好。私人银行专业化服务成效日益凸显，截至报告期末，私人银行投资理财类产品的覆盖度较年初提升1.23个百分点。信用卡业务方面，集团聚焦金领贷客群、房贷客群，将信用卡打造成为增强零售优质客群粘性的有效载体。截至报告期末，信用卡累计发卡量126.42万张，贷款规模41.89亿元。提升金融市场业务创新转型发展能力 树立行业口碑报告期内，集团金融市场业务坚决践行转型振兴高质量发展要求，以建设市场领先的金融市场FICC业务中心为目标，牢牢守住风险底线，深耕同业客户基础，强化销售交易能力建设，确保全行流动性安全，金融科技赋能业务发展，坚持金融服务实体经济，各项工作取得显著成果。理财业务方面，集团持续丰富理财产品种类，优化产品功能，为客户提供更好的理财服务。同时积极拓展行外代销渠道，拓宽资产管理服务客群，已与26家机构达成代销合作。报告期内，集团共发行理财产品204只，销售金额合计2,048.85亿元。截至报告期末，集团存续理财产品358只，理财产品余额1,677.01亿元，净值型产品占比91.72%。资金业务方面，密切关注市场走势，加强市场研判，积极开展各类货币市场交易业务，上半年开展人民币债券质押式回购交易约5.57万亿元，同比增长5.96%，获得中国人民银行2024年度公开市场业务一级交易商资质，并获评中国外汇交易中心回购活跃交易商，大幅提高银行间市场影响力。同时，紧抓市场机遇，踊跃参与外汇交易中心各类标准化交易业务，外汇交易各项排名较上年同期均有不同程度的提升，其中人民币外汇掉期交易排名跻身银行间市场45强。债券业务方面，持续加强债券业务模式和产品创新，做大债券投资交易规模，债券市场影响力、货币政策传导能力、双边做市服务能力有效提升。报告期内，各类金融市场债券业务量保持稳步增长，现券交易量2.9万亿元，同比增长70%。同业业务方面，集团持续探索并推进同业客户一体化经营。继续完善同业产品货架，以销售促转型稳步推进，客户综合贡献稳步提升，同业朋友圈更加丰富完备。报告期内，实现属地目标同业客户覆盖率43.4%，多元产品渗透率34.81%。同业授信方面，报告期内，境内外同业机构对集团授信额度充足、品种广泛，满足全行各项业务稳定发展需要。截至报告期末，集团累计获得超过1,300家同业机构授信，授信总额1.6万亿元人民币。聚焦数字金融和智慧金融 持续推进网络金融业务报告期内，集团网络金融业务聚焦数字金融和智慧金融，持续推进线上用户运营和门户渠道建设，通过技术与数据赋能，加速实现综合化服务升级和经营转型发展。手机银行方面，集团重点围绕账户银行、财富银行和生态银行战略定位，逐步从功能建设向客户经营转型并成功升级至6.3版，通过建立事件型营销体系和数字化全域经营促进移动端月活客户数量和财富产品成交量持续提升。门户网站方面，集团于2024年5月完成门户网站系统重构，实现全面升级，为客户提供智能化服务新体验。在生态化经营方面，集团持续深耕教育服务场景，深化场景化服务新模式，打造全方位服务客户的生态体系。展望未来2024年下半年，集团将全面落实监管政策要求，遵金融规律、守金融向善、求金融真实，以改革精神做强主责主业，更加注重统筹联动，更加注重突出重点，更加注重实绩实效，持续集中全力转方式、调结构、提质量、增效益，努力开创高质量发展新局面。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
JCB and Permata Launch the Permata JCB Ultimate Card JCN Newswire

JCB and Permata Launch the Permata JCB Ultimate Card

August 30, 2024
TOKYO & JAKARTA, Aug 30, 2024 - (JCN Newswire via SeaPRwire.com) - PT JCB International Indonesia, a subsidiary of JCB International Co., Ltd. (JCB) and PT Bank Permata Tbk (Permata) have launched the Permata JCB Ultimate Card, designed to provide the best experience for its users, especially travel and dining enthusiasts. This card targets the affluent segment looking to enjoy more benefits from credit card transactions.The Permata JCB Ultimate Card offers special deals through a Welcome Bonus Program of 20,000 airline miles and product benefits where every dining transaction of IDR 5,000 can be exchanged for 1 airline mile, subject to the terms and conditions. The launch of this credit card demonstrates PermataBank’s commitment to providing a card that is not just a payment tool, but also adds value to PermataBank customers according to their lifestyles.PermataBank’s Consumer Banking Director, Djumariah Tenteram, said, “The Permata JCB Ultimate Card is our first collaboration with JCB and is aimed at the affluent segment that wants the best experience, particularly in traveling and dining. This credit card launch also reflects PermataBank’s commitment to providing a payment tool that adds value to its customers according to their lifestyles. With this strategic collaboration, we are confident that the Permata JCB Ultimate Card will enhance and expand the services we provide to our loyal PermataBank customers, especially those in the affluent segment.”The affluent segment bridges the gap between the middle economic class and high-net-worth individuals. According to recent studies on the affluent segment in Southeast Asia, this segment in Indonesia accounts for 9% and contributes over 30% of household wealth. Most of them are aged between 20 and 49 years old. By 2030, their number is expected to triple significantly.“The partnership with PermataBank allows us to extend our reach to credit card users in Indonesia. PermataBank is a strategic partner for JCB due to its ability to reach the affluent segment. We believe that the convenience of the transactions offered, together with access to unique experiences and exclusive Japanese services, will add value to credit card users in Indonesia,” said Yoshiki Kaneko, President & CEO of JCB International Co., Ltd.The Permata JCB Ultimate Card offers a Welcome Bonus of 20,000 miles for PermataBank Priority customers who make transactions totaling IDR 25,000,000 or more per month for three consecutive months after the card is approved. In addition, cardholders earn 1 reward point equivalent to 1 KrisFlyer mile or 1 GarudaMiles for every dining transaction of IDR 5,000 or other retail transactions of IDR 10,000.Djumariah Tenteram, Director of Consumer Banking at PermataBank, added that the Permata JCB Ultimate Card is designed to provide exclusive opportunities for PermataBank's private and priority customers to enjoy various benefits. We hope that the Permata JCB Ultimate Card will add significant value and support the growth of PermataBank's credit card customers in the future.Permata JCB Ultimate Cardholders can also enjoy a variety of promotional programs from JCB, such as discounts of up to 25% at more than 100 Japanese restaurants in Indonesia that have partnered with JCB. Furthermore, cardholders have access to various promotions at renowned merchants in Japan, such as 10% cashback at Premium Outlets such as Gotemba and 8% cashback at Don Quijote from October 2024, as well as premium experiences such as medical check-ups or beauty treatments, and many other exciting promotions.JCB’s Ultimate services are also available to further complement the lifestyle needs of Permata JCB Ultimate Cardholders, including complimentary access to JCB Plaza Lounge, access to JCB Concierge Desk services, and 8x access to airport lounges with LoungeKey in countries and regions, such as Malaysia, Singapore, Thailand, China, South Korea, Taiwan, Vietnam, Germany and the UK, in addition to 8x access to non-LoungeKey lounges in Japan and Hawaii.To enhance this special offer, the top 50 Priority Banking customers with the highest transaction value from September to December 2024, who have made retail transactions totaling IDR 160 million or more, will have the opportunity to receive free return Business Class tickets for Jakarta-Tokyo, subject to the terms and conditions.The premium design of the Permata JCB Ultimate Card exudes elegance and luxury with a combination of sakura and blue, the color that represents loyalty (from the term “true blue”). Cardholders will be pampered with a variety of tempting offers that will allow them to explore a world infused with the Japanese lifestyle, offered by JCB.ABOUT PERMATABANKPermataBank is one of the top 10 banks in Indonesia by assets in the banking industry. Listed on the Indonesia Stock Exchange (Code: BNLI) with controlling shareholder Bangkok Bank Public Company Limited, PermataBank is at the forefront of digitalization with innovative products and services serving over 6.2 million customers in 61 cities across Indonesia. As of June 30, 2024, PermataBank has 212 branches & cash offices, Sharia branches, and mobile branches; 830 ATM locations and over 22,000 cardless cash withdrawal outlets in Indomaret, access to over 100,000 ATMs (VisaPlus, Visa Electron, MasterCard, Alto, ATM Bersama, and ATM Prima networks), and millions of other ATMs worldwide connected to Visa, Mastercard, Cirrus networks.PermataBank has received various service excellence awards in the categories of General Bank and Sharia Business Unit, such as the Banking Service Excellence Award 2024 from InfoBank magazine in collaboration with Market Research Indonesia, Silver awards from the Asia-Pacific Stevie Awards 2024, The “Best Disclosure and Transparency” and Top 50 Emitters with the Largest Market Capitalization (Big Cap) - Best Corporate Governance from IICD CG Conference and Award 2023.As a pioneer of digital innovation in the Indonesian market, customers can experience comprehensive digital services such as the super app mobile banking, PermataMobile X with over 200 superior features, PermataNet internet banking, Permata e-Business, PermataQR Pay at over 300,000 merchants, point of sales at over 20,000 merchants, API banking with 200 types of APIs, call center services with interactive voice response and artificial intelligence voice recognition. Customers can also experience Modernized Branches in selected regions in Indonesia offering a simple, fast, and reliable experience at several branches.For more information about PermataBank, visit our website at http://www.permatabank.comContactMELINDA HOESAINDepartment Head, Corporate AffairsTEL: +62 21 523 7788Email: corporate.affairs@PermataBank.co.id CHICILIA WONGSODIREDJOID COMM for PermataBankTEL: +62 878 866 555 10Email: chicilia@idcomm.id ABOUT JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 49 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 158 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/ContactKosuke OchiaiCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2024 JCN Newswire via SeaPRwire.com.
More
JCB and BINDO Launch World’s First Metal JCB Card JCN Newswire

JCB and BINDO Launch World’s First Metal JCB Card

August 30, 2024
TOKYO & HONG KONG, Aug 30, 2024 - (JCN Newswire via SeaPRwire.com) - JCB International Co., Ltd., the international subsidiary of JCB Co., Ltd. (“JCB”), Japan’s only international payment brand, and BINDO LABS LIMITED (“Bindo”), the parent company and developer of Wonder, a leading payments and fintech platform in Asia Pacific, announced the launch of the Wonder x JCB Metal Corporate Card on August 30, 2024.This is the first JCB Metal Card issued globally. In addition to its premium metallic feel and look, the Wonder x JCB Metal Corporate Card has various innovative and bespoke features, including:Fast Virtual Card Issuance: Our efficient card issuance service ensures that you can receive your new virtual card in as little as 7 minutes. The physical metal card is expected to arrive within 5 days.Global Acceptance: Cardholders can enjoy convenient payments at 49 million of JCB merchants worldwide.Beneficial Services: Cardholders can enjoy exclusive JCB benefits and offers, including perks related to business travel, dining, and entertainment. For more details, please visit here.Designed for Corporate Use: Ideal for company operations and business expenses, allowing company owners and employees to easily manage operational costs and business entertainment by settling credit card bills directly.Administrative Cost Savings: By using a corporate credit card for transactions, the company pays bills directly, eliminating the need for employees to report business expenses individually. This reduces the workload of the finance department and saves on administration costs. In addition, the company can view detailed transaction records through the Wonder App to consolidate business expenses.Superior Security: Advanced encryption technology is used to ensure the security of every transaction.Over the next 12 months, Bindo expects to increase the number of Wonder x JCB Metal Corporate Cardmembers by approaching thousands of its own customers via Wonder, an all-in-one digital payments and financial services platform, with scope for further expansion across different industries and verticals.Built on mutual trust, innovation and dedication, JCB and Bindo are both committed to continuing to drive financial innovation and improve financial access for merchants of all sizes and industries in Hong Kong and the wider Asia-Pacific region.Mr. Jason Ngan, the founder and CEO of Bindo, commented:"We are very happy to announce our collaboration with JCB on the Wonder x JCB Metal Card issuing. This partnership marks an exciting milestone for Wonder, as it aligns perfectly with our mission to enable all merchants, big or small, to pay and get paid effortlessly. By combining our cutting-edge technology with JCB’s extensive network and expertise, merchants can now create a JCB corporate card with just a click of a button and streamline its financial management, effectively uplifting access to financial services for the traditionally underserved segments such as small to medium enterprises. We are confident that this collaboration will bring unparalleled benefits and convenience to our customers, and we look forward to a successful partnership with JCB."Mr. Tomoya Ichino, Managing Director of JCB International (Asia) Ltd., added:"We are very pleased to launch the world's first metal JCB Card. Bindo has achieved the remarkable introduction of a seamless card payment experience for taxi rides in Hong Kong, sparking a wave of momentum and citywide excitement. Bindo's technological capabilities and transformative offerings have truly set them apart as an industry-leading company. JCB will continue to strive to offer services with a particular focus on Hong Kong and Japan for a customer satisfaction. Together with Bindo, a pioneer in the market combining innovative technology with creative thinking, we will bring value and convenience to JCB cardmembers in Hong Kong. We anticipate the launch of many more cards in the future as we work together to push the boundaries of payment technology."About BINDOBindo Labs is the parent company and developer of Wonder, a leading payments gateway and FinTech platform for merchants in Hong Kong and Asia Pacific. Before Wonder, Bindo Labs began its journey as the leading payment and software solutions provider to banks, financial institutions and merchants globally, with offices in Hong Kong, Japan, Singapore, Malaysia and Mainland China. Since inception, over 10,000 merchants globally have used Bindo’s software to process more than USD 10 billion.Today, Bindo Labs is disrupting digital payments with the launch of an innovative payments gateway and FinTech platform: Wonder. Wonder is Hong Kong’s first fully digital omni-channel payment gateway platform where any merchant can self-KYC online in minutes, open an account, collect all payments and manage transactions from a single mobile app. Moreover, Wonder has pioneered instant payments settlement (T+0) in Hong Kong.Headquartered in Hong Kong, Bindo Labs raised its USD 6 million series A funding round in 2021 led by Hong Kong Telecom (HKT). Currently, Bindo Labs has offices in Hong Kong, Japan, Singapore, Malaysia, Shenzhen, and Changsha.For more information, please visit: https://wonder.app/About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 49 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 158 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide.For more information, please visit: www.global.jcb/en/ContactKosuke OchiaiCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2024 JCN Newswire via SeaPRwire.com.
More
PlugMan 在东京带来无眼镜 3D 视频体验 Business

PlugMan 在东京带来无眼镜 3D 视频体验

August 30, 2024
(SeaPRwire) - 东京，日本，2024 年 8 月 29 日 -- 一项突破性的 3D 裸眼视频体验在涩谷推出，以标志性角色为特色，模糊了第四象限与现实之间的界限。这个身临其境的装置位于东京涩谷区静冈町 3 丁目 22-22-9，将持续到 9 月底。 , 一个多元宇宙和数字角色，旨在彻底改变我们与数字资产、游戏和身份在世界中的互动方式。 3D 投影以令人惊叹的景象将 PlugMan 带入生活，超越了媒体的界限。此次活动有望成为一场视觉盛宴，提供独特的机会体验尖端技术与艺术表现力的融合。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 联系：Ellwood Chen PlugMan ellwoodche-at-plugman.xyz https://plugman.xyz/
More

Hua Medicine Announces 2024 Interim Results

August 30, 2024
- Dorzagliatin (trade name: HuaTangNing, world's first dual-acting glucokinase activator (GKA), successfully entered China’s National Reimbursement Drug List for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (the “NRDL”) at the end of 2023. Hua Medicine worked with sales promotion partner Bayer Healthcare Company Limited (“Bayer”) and 80 Tier 1 distributors to begin the pharmaceutical market entry in 31 municipalities and provinces in China.- The new NRDL became effective on January 1, 2024. In the first half of 2024, the sales volume of dorzagliatin increased significantly. As of June 30, 2024, sales of HuaTangNing reached 846,000 packs with a sales revenue of RMB102.7 million. The sales revenue increased by 46%, compared with the six months ended June 30, 2023.- Dorzagliatin experienced a fast entry into hospitals, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. By the end of June 30, 2024, dorzagliatin was prescribed in over 2,100 hospitals and over 2,900 pharmacies. Dorzagliatin was sold principally through hospitals (approximately 72% of total sales), with the remainder of sales through pharmacies (20%) and internet drug stores (8%).- Gross profit in the first half of 2024 is RMB47.8 million, representing a gross profit margin of 46.5%. Bank balances and cash position increased by 51.9% to approximately RMB1,338.8 million for the six months ended June 30, 2024, compared with the six months ended June 30, 2023.- Dorzagliatin manufacturing capacity continues to expand, with the expectation to reach 3 million packs in 2024. New processes for larger capacity have been established with our partners and are under regulatory review for production permit.- Post marketing clinical studies proceeded at an accelerated rate, in which HMM0601 enrolled 1,368 patients and HMM0701 enrolled 102 patients. HMM0601 is designed to evaluate the long-term safety of dorzagliatin by collecting 1-year clinical safety data in 2,000 T2D patients and HMM0701 is a prospective real-world study to explore dorzagliatin’s clinical beneficial effects on the improvement of glucose homeostasis, cognitive function and diabetes remission. A good drug safety profile for dorzagliatin has been observed since its commercial launch in October 2022 – a time span of over 20 months and approximately 100,000 patient exposure.- Two Mendelian randomization studies conducted by our collaborating Hong Kong-based clinical investigators, and published in Cardiovascular Diabetology showed that glucokinase activation can lead to long term benefits in reduction of risks in cardiovascular diseases and dyslipidaemia. New clinical indications shall be further explored with our commercialization partner.HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company’s business progress for the first half of the year and business outlook.Dr. Li Chen, the founder and CEO of Hua Medicine, said, “The first half of 2024 marks a milestone for the commercialization efforts of Hua Medicine. Dorzagliatin's successful inclusion in China’s National Reimbursement Drug List has significantly improved patient accessibility and affordability. Against the backdrop of comprehensive support from the national and local governments for the development of the biopharmaceutical industry, and with the joint efforts of the Company, commercial partners, and production partners, the production capacity of dorzagliatin is rapidly increasing, accelerating its entry into hospitals and pharmacies nationwide to benefit more patients. With the continued growth in the number of users, the safety of dorzagliatin has been well validated, and its economic and social benefits have also greatly increased, instilling confidence in the Company's future development. Through sales expansion and operational optimization, we hope to achieve profitability for the Company by 2025. Currently, Hua Medicine is also conducting basic and clinical research on dorzagliatin globally, aiming to continuously expand its indications and target populations, explore new disease areas, and promote human health and well-being.”Progress of Clinical Research and Company Operations- During the first reporting period under the NRDL, dorzagliatin experienced a fast entry into hospital and pharmacies, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. The number of hospitals prescribing dorzagliatin exceeded 2,100 in the first half of 2024.- Revenue of dorzagliatin reached RMB102.7 million in the first half of 2024 and is expected to continue to grow in the second half of 2024. As we build off our new foundation under the NRDL, we plan to leverage our well-established partnerships to enhance the dorzagliatin manufacturing process, which is expected to lead to efficiencies, expanded capacity and reduction of cost of goods.- We continued our post marketing clinical studies at approximately 80 hospitals to better understand the benefits dorzagliatin provides to patients with Type 2 diabetes and T2D complications, such as memory loss and diabetes kidney disease. Through our collaboration with our clinical research partners in Hong Kong, we have discovered that glucokinase (GK) activation may bring the benefits of reduction of risks in cardiovascular disease, and dyslipidemia. These results (applying the Mendelian Randomization (MR) methodology) certainly expand our understanding of the benefits of GK activation through dorzagliatin and for uncovering new indications of dorzagliatin in the future. Mendelian Randomization (MR) is a statistical method that uses genetic variants to investigate the causal effects of exposures (e.g., treatments) on outcomes (e.g., diseases). Its unique advantage lies in its reduced susceptibility to confounding and time-related biases compared with observational studies, which is achieved by leveraging the random allocation of genetic variants at conception. In evidence-based medicine, the credibility of evidence from MR is considered to be among the highest, second only to that of randomized controlled trials.- We have advanced our post-marketing real world evidence (RWE) studies HMM0601 and HMM0701 in T2D patients in China, and HMM0123 in Hong Kong, China. In these studies, we are collecting evidence in medical practices for optimization of glucose homeostasis either through dorzagliatin alone or in combination with standard care T2D medications such as metformin, DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1RA and insulin. These results create new evidence for dorzagliatin in the expansion of its indication in diabetes prevention and remission.- We are continuing our drug development pipeline with focus on the fixed dose combination (FDC) of new drug candidates. The new drug Dorzagliatin-Metformin FDC entered manufacturing process validation and our plan is to launch this new medicine for Type 2 diabetes in 2028. Additional new FDC drugs with dorzagliatin will be developed for T2D patients, tailored specifically to address T2D patients with associated complications such as obesity and diabetes kidney disease.- To further leverage the unique advantage of dorzagliatin in restoring GLP-1 secretion in patients with diabetes and obesity, Hua Medicine initiated its Phase I study in the United States with our 2nd generation GKA. The trial has been proceeding smoothly and has already completed dose escalation in three cohorts of T2D patients in the United States. The topline data is expected to be available in the fourth quarter of 2024, supporting future drug development.- At the American Diabetes Association (ADA) Annual Meeting 2024, Hua Medicine reported new scientific data supporting the combination of dorzagliatin with a SGLT-2 inhibitor which led to improvement in glycaemic control. Combination of dorzagliatin with chronic kidney disease (CKD) medicine, such as SGLT-2 inhibitor, empagliflozin, in mid to late stage diabetes kidney disease patients, offers new opportunity to expand dorzagliatin’s indication.- We are exploring more drug repurposing opportunities for dorzagliatin using MR framework, such as renal diseases, neuropathy related diseases, eye related diseases, cognitive disorders, and cancers. Animal studies shall be further performed to validate the promising findings.- We are continuing to optimize our protein allosteric modulation technology (PAMT) and expansion from positive allosteric modulator (PAM), such as GK positive allosteric modulator dorzagliatin, to negative allosteric modulator (NAM) in kinase and G-protein-coupled receptors (GPCR) proteins. The GK NAM program advanced to the pre-clinical candidate (PCC) selection stage and final optimization of the PCC to clinical candidate for congenital hyperinsulinism (CHI), and potentially for dyslipidaemia. We continue to advance mGLUR5 NAM program for its clinical potential in Parkinson’s disease (PDLID), Fragile X syndrome (FXS), and drug addiction.Financial highlightsAs of June 30, 2024,- Bank balances and cash position was approximately RMB1,338.8 million.- Total revenue generated by the Company was approximately RMB102.7 million, reflecting sales of approximately 846,000 packs of HuaTangNing .- Total other income was approximately RMB55.1 million, of which approximately RMB47.8 million was attributable to the amortization of Bayer milestone income.- Total expenditures was approximately RMB245.9 million, of which approximately RMB119.8 million was attributable to research and development expenses.Forward-looking StatementThis article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product. The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect as a result of various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin on hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.comDisclaimerFor the accuracy and completeness of the context, references to information related to products launched in China, especially label or requirements, should follow the relevant documents approved by the Chinese regulatory authorities.The above information should not be interpreted as a recommendation or promotion of any drug or treatment regimen, nor should it substitute for the medical advice of any healthcare professional. Please consult a healthcare professional for any matters related to medical treatment. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

复星国际未来产业发展和赢利更可预期

August 30, 2024
香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 2024年8月28日，复星国际（HKEX: 0656）公布2024年中期业绩。报告期内，总收入保持增长，达人民币978.4亿元；产业运营利润保持增长，达人民币34.7亿元，归母净利润为人民币7.2亿元。复星国际董事长郭广昌在29日上午的业绩发布会上表示，「上半年，尽管宏观环境充满挑战，我们坚定执行聚焦主业战略，围绕形成优势的产业赛道，打造行业数一数二的好公司、好产品，总体来看卓有成效。我们将持续聚焦创新、聚焦全球化，同时注重轻资产运营，以具备竞争优势的核心能力驱动长远发展。」今年以来，国内经济恢复不稳固，国际市场持续波动，让包括复星在内的中国企业面临诸多挑战。复星持续推进战略聚焦，以核心能力驱动企业发展，实现核心产业提质增效，资产底盘保持稳健。分析人士认为，从复星中期业绩报告释放的信息来看，复星聚焦家庭消费核心产业，先人一步推进创新和全球化，这一战略持续为复星夯实业务底盘，带来可预期的稳定赢利；同时，这两年复星积极推进轻资产运营，优化资产组合，持续降低杆杆，现金储备充裕，财务安全垫日渐厚实，有望推动市场对复星的价值进行重估。全球化和创新「先人一步」，打造「数一数二」的企业和产品 今年上半年，复星四大核心子公司——复星医药、豫园股份、复星葡萄牙保险、复星旅文，总收入达人民币721.7亿元，占集团总收入的比重达到74%。复星聚焦主业的效果进一步显现，其在医药、旅游、消费、保险等核心产业赛道的优势持续提升。在上述核心赛道，通过多年努力，复星已打造出多个在行业排名前列的「数一数二」的企业和产品。例如，复星医药位列中国医药工业百强第二名，今年上半年也连续第三年入选全球药企管线规模前二十强；复宏汉霖是首个在港股赢利的中国创新生物制药公司，旗下多款自主开发的单抗生物类似药，引领中国生物医药行业快速发展，首款重磅产品汉利康是首个获批上市的国产生物类似药；复星葡萄牙保险在葡萄牙保险市场市占率保持第一，在全球葡语区保险市场居前列；智造板块的翌耀科技是全球领先的自动化和数字化企业。此外在快乐业务板块，复星旅文旗下Club Med是精致「一价全包」度假的全球领导者；三亚亚特兰蒂斯是国内领先的高端综合度假旅游目的地，推动海南旅游进入3.0时代；豫园旗下老庙黄金，是中华老字号，更是享誉全国的珠宝品牌。这些在各自行业「数一数二」的企业和产品，帮助复星持续巩固在相关产业的领导地位。对复星而言，稳健赢利的增长来自两个方面，一是创新，一是全球化。在当前国内经济「内卷」的大环境下，「出海」成为企业界的「必答题」。但复星早在2007年便启动全球化征程，在海外摸爬滚打17年，今天已成为植根中国的标杆性的全球化企业之一、在全球超过35个国家和地区拥有深度产业布局。17年出海征程里，复星捕获了很多成功的项目，也遇过很多挑战，最重要的意义在于锻造了国内企业稀缺的全球化能力，并在全球打通不同市场、不同业态和资源，实现了全球布局、全球运营和全球发展，全球化深度运营能力持续提升。有一组数据非常能阐释情况，2024年上半年，集团海外收入达人民币458.7亿元，同比增长4%，占总收入的比重上升至47%，近半收入来自海外，这在中国企业中并不多见。更重要的是，复星在全球化过程中积极推进旗下企业生态赋能与协同，旗下海内外成员企业在全球化研发、业务拓展、运营及投融资等方面取得多项进展。上半年，复星旗下企业的生物药出海再获突破。复星旗下的复宏汉霖，自主开发的汉曲优获得美国食品药品监督管理局批准上市，成为在中国、欧盟、美国获批的「中国籍」单抗生物类似药；中国首个生物类似药汉利康获得秘鲁药监局批准上市，成为继汉曲优和汉斯状后，复宏汉霖第三款海外获批上市的自研药品。再如复星旅文Club Med地中海俱乐部在全球运营67家度假村，2024年上半年营业额再创新高，达人民币88.9亿元，同比增长10.3%。其中，欧非中东及美洲区持续增长，亚太区复苏显著。2024年5月，Club Med 在阿曼签约中东首个度假村。复星葡萄牙保险，从葡萄牙出发积极拓展海外市场，今年上半年取得葡萄牙境内和国际业务双增长，海外业绩占比进一步提升，国际业务录得总保费欧元8.85亿元，占比超过30%；国际业务净利润约欧元0.51亿元，占比超过40%。复星旗下全球领先的自动化和数字化企业翌耀科技，也在静悄悄推进海外拓展，2024年上半年海外新增订单达到人民币39.9亿元，其中美国市场订单大幅增加，新增订单达到人民币7.5亿元，同比增长超过一倍。创新同样是复星长期积累并始终坚持的核心能力。报告期内，复星持续深化科技与创新能力，创新投入达人民币35亿元；全球视野下的整合式创新模式更加成熟，一批突破性成果正持续为复星带来稳健赢利，成为复星的增长动力。从创新药研发方面来看，复星医药共有4个产品共9项适应症获批上市，4个产品共9项适应症进入上市前审批/关键临床阶段，9项产品（按适应症计算）获批开展临床试验。复宏汉霖自主研发并生产的创新生物药不断取得突破性进展，全球首个一线治疗小细胞肺癌的抗PD-1单抗汉斯状已获批4项适应症，累计惠及患者超7.5万，对外授权覆盖美国、欧洲、东南亚、中东和北非等70多个国家和地区。此外，新一代口服血小板生成素受体激动剂（TPO-RA）苏可欣新适应症也获得国家药监局批准。尖端医疗器械及创新疗法的布局也取得新进展。2024年6月，直观复星总部产业基地在上海启用，是直观医疗在亚太地区最大的研发、生产和培训一体化基地，达芬奇手术机器人国产化显著提速。直观复星Ion支气管导航操作控制系统也于2024年3月通过国家药监局批准，并于7月上市。 「轻资产运营」打法成型，价值重估可期得益于业务面的坚实支撑，复星财务面也持续改善。报告期内，复星持续优化资产组合，降低杆杆，财务状况保持稳健。截至报告期末，集团调整后总债务占总资本比率为50.2%，维持了2020年以来的下降趋势；调整后NAV为每股港币17.4元，显示当前复星国际股价被严重低估。复星也在积极夯实财务安全垫，保持充裕的现金储备。这次报告期内，复星国际现金、银行结余及定期存款达到人民币1095.5亿元，较2023年底增加人民币约171亿元。上市17年来，累计分红港币256亿元，分红率逐渐提升，近五年分红率在20%及以上。就在 2024年6月，国际评级机构标普也充分肯定复星财务战略成效，确认评级展望为「稳定」。在通过持续的创新和全球化实现稳定赢利的同时，复星面对新的市场环境，也继续推进「瘦身健体」，陆续退出一些非核心产业，同时积极推进「轻资产运营」，打法也逐渐成型。2024年5月，复星出售德国私人银行HAL 99.74%股份，引起市场关注，交易完成后，复星将不再持有HAL股份，但全额保留HAFS基金服务业务，以轻资产运营模式，管理约千亿欧元资产。在文旅赛道，复星的轻资产运营模式成效显著，Club Med、三亚亚特兰蒂斯、太仓阿尔卑斯等IP成为国内旅游行业标杆。报告期内，Club Med采用租赁及管理模式的度假村占比为85%，自持度假村占比降至15%。2024年4月，复星旅文在丽江地中海国际度假区打造的全新IP——阿美泽雪山营地对外开放后，迅速火爆「出圈」，带动度假区内Club Med丽江度假村与丽江地中海棠岸度假酒店入住率显著提升。2024年6月，复星旅文还携手太仓市政府共同打造一站式冰雪主题旅游度假目的地太仓阿尔卑斯国际度假区二期。该项目总投资超人民币50亿元，由太仓市政府平台出资打造，由复星旅文运营管理。此前复星旅文对阿尔卑斯雪世界的成功运营，为二期项目提供了信心和动力，该项目有望打造多项「世界雪场之最」。与此同时，复星携手合作伙伴打造了一批产业基金，深度布局优势产业。2024年3月，复星医药依托在生物医药领域的领先优势，联手深圳市引导基金等其他七方投资人，共同出资设立人民币50亿元生物医药产业基金，募集资金全部投资于生物医药、细胞和基因等领域。复星医药旗下复健资本通过深圳市公开遴选中标，独家管理该基金。4月，深圳市政府与复星签署战略合作框架协议，双方集聚优质创新资源，进一步加强在生物医药、文体旅游、时尚消费等领域的合作。也是在2024年4月，复星创富联合武创投、武汉基金，设立人民币30亿元产业基金，首期规模人民币11亿元。这是湖北省设立人民币200亿元政府引导基金以来，第一只出资的市场化基金，主要聚焦新一代信息技术、双碳、智能制造、大消费四大赛道。面对当前的市场环境，可以预计，未来复星仍将积极推进轻资产运营，持续扩大「朋友圈」，加强与各方深度合作，通过优势互补，实现共赢。多位市场分析人士认为，复星通过创新和全球化的核心战略，推动业务实现持续稳定盈利，通过退出非核心产业、轻资产运营，持续降债等措施，保持财务面的稳健，有望推动市场对复星的价值重估。郭广昌认为，未来投资者会更加看重核心产业增长和现金流的稳健，「一次性的资产出售都是短期的，核心业务的成长，才是企业稳健赢利的核心因素」，复星希望打造一个聚焦核心产业的家庭消费产业集团，产业的发展和赢利更可预期。无论是集团层面还是每一块业务，都要给客户、投资人提供风险可控、能稳健成长的企业价值。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More

华领医药公布2024年中期业绩

August 30, 2024
- 全球首创新药双功能葡萄糖激酶激活剂（GKA）多格列艾汀（商品名：华堂宁®）于2023年底成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录》（“国家医保药品目录”）。华领医药与商业化合作伙伴拜耳以及80家一级经销商共同推动多格列艾汀的商业化，开始进入中国31个省级医药市场。- 2024年1月1日新版“国家医保药品目录”正式执行，2024年上半年，多格列艾汀的销售量显著增加。截至2024年6月30日，共销售84.6万盒，实现销售收入人民币1.027亿元，相比2023年6月30日，同比增长46%。- 得益于政府支持创新药品的市场准入政策，多格列艾汀加速进入上海、北京和天津等地医院。截至2024年6月30日，已有2100多家医院和2900多家药店开始了多格列艾汀的处方销售。多格列艾汀在医院、药店和网络药店销售的比例分别为72%、20%和8%。- 2024年上半年，公司毛利约为4780万元，毛利率为46.5%。截至2024年6月30日，公司银行结余及现金约13.388亿元，相比2023年6月30日，同比增长51.9%。- 多格列艾汀的生产能力继续扩大，预计2024年产能将达到300万盒以上，公司已经与合作伙伴建立了更大产能的新工艺，正在接受生产许可部门的监管审查。- 上市后临床研究加速进行，其中HMM0601研究已入组1368例患者，该研究旨在通过收集2000例2型糖尿病患者1年的临床安全性数据来评估多格列艾汀的长期安全性。HMM0701研究已入组102例患者，该研究是一项前瞻性真实世界研究，旨在探索多格列艾汀在改善血糖稳态、认知功能和糖尿病缓解方面的临床获益。自2022年10月上市销售以来，过去20个月约有10万名患者使用多格列艾汀，药物安全性良好。- 公司与中国香港临床研究人员合作开展了两项孟德尔随机化研究，结果显示，激活葡萄糖激酶（GK）在降低心血管疾病风险和血脂异常风险方面具有长期获益性，研究结果已经发表在《心血管糖尿病学》杂志上。公司将携手商业化合作伙伴进一步探索多格列艾汀更加广泛的临床适应症。香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 华领医药（“公司”，香港联交所股份代号：2552）宣布公司及其附属公司截至2024年6月30日止，6个月（“报告期”）未经审核的综合业绩，以及公司上半年业务进展和未来业务展望。华领医药创始人、首席执行官陈力博士表示：“2024年上半年是华领医药商业化进程的又一个里程碑。多格列艾汀成功纳入国家医保药品目录，大大提升了患者用药的可及性和可负担性。在国家和各级政府全链条支持生物医药产业发展的背景下，在公司与商业化伙伴和生产伙伴的共同努力下，多格列艾汀正迅速提升产能，加速进入全国各地的医院和药房，以惠及更多患者。随着用药人数的持续增长，多格列艾汀的安全性得到了良好的验证，其经济效益和社会效益也大幅提升，为公司未来发展注入了信心。通过销售扩张和优化运营，我们希望能够在2025年实现公司盈利。目前，华领医药还正在全球范围内开展多格列艾汀的基础研究和临床研究，希望不断拓展多格列艾汀的适应症和适用人群，探索更加广泛的疾病应用领域，造福不同的患者人群。”临床研究和公司运营进展摘要- 进入国家医保药品目录后，多格列艾汀速进入医院和药店，尤其在上海、北京、天津等城市，政府推出了支持创新药进入市场的政策。截至2024年上半年，多格列艾汀已经进入全国2100多家医院。- 上半年，多格列艾汀实现销售收入人民币1.027亿元，预计在2024年下半年将继续增长。基于进入医保建立的新基础，公司正不断与合作伙伴密切协作，优化多格列艾汀的生产流程，提高生产效率，从而扩大产能并降低生产成本。- 公司继续在约80家医院开展上市后真实世界研究，增进了解多格列艾汀对于2型糖尿病及其并发症（如记忆力减退、糖尿病肾病）患者的获益。除此之外，通过与中国香港的临床研究伙伴的合作，我们使用孟德尔随机化(MR)研究发现激活GK可以降低心血管疾病和血脂异常风险，有助于公司通过多格列艾汀进一步了解GK激活的更多获益，并探索多格列艾汀新的适应症。孟德尔随机化是一种统计方法，利用遗传变异体来研究暴露（如治疗）对结果（如疾病）的因果效应。MR的独特优势在于它比传统的观察性研究更不容易受到混杂因素和时间相关偏倚的影响，因此在循证医学中，当随机对照试验不可实施时，MR被视为最高循证医学证据。- 公司正在积极推进针对2型糖尿病患者的上市后真实世界研究，包括在中国内地的HMM0601研究和HMM0701研究，以及在中国香港的HMM0123研究。在这些研究中，公司正不断积累多格列艾汀单独用药，以及多格列艾汀与二甲双胍、DPP-4抑制剂、SGLT-2抑制剂、GLP-1RA和胰岛素等联合用药的临床数据，以优化血糖稳态治疗的临床证据，并且为多格列艾汀拓展在糖尿病预防和缓解等方面的适应症提供新的证据。- 公司正在持续丰富药物开发管线，尤其是固定复方制剂的开发。多格列艾汀-二甲双胍固定复方剂量已经进入生产工艺验证阶段，公司预计将于2028年推出2型糖尿病治疗的新药。未来，公司将开发更多的多格列艾汀固定复方制剂新药用于糖尿病及其并发症，如肥胖、糖尿病肾病等的个性化治疗。- 为了进一步发挥多格列艾汀在修复伴有肥胖的糖尿病患者的GLP-1分泌方面的独特优势，公司在美国启动了第二代GKA的1期临床研究。目前，试验进展顺利，在3组2型糖尿病患者中完成了剂量递增。公司预计在2024年第四季度发布顶线数据，以支持未来的药物开发。- 在2024年美国糖尿病协会（ADA）科学年会上，公司报告了多项基础研究和临床研究进展。一项研究显示，多格列艾汀联合SGLT-2抑制剂可以改善血糖控制，联用效果优于两者单独用药，并且提示多格列艾汀有望在新的适应症中发挥作用，用于与SGLT-2抑制剂恩格列净等慢性肾病治疗药物联合用药，治疗中晚期糖尿病肾病患者。- 公司正在使用孟德尔随机化研究的框架探索多格列艾汀更多的药物使用机会，如肾病、神经病变相关疾病、眼部相关疾病、认知障碍和癌症等。公司将进一步利用动物研究验证更多可能的机遇。- 公司将持续优化蛋白变构调节技术，并积极扩展应用领域，推进负向变构调节剂在GK和GPCR蛋白上的应用。目前葡萄糖激负向变构调节剂已经进入临床前药物候选阶段，作为先天性高胰岛素血症和潜在的血脂异常症的临床候选药物。公司将继续推进mGLUR5 NAM项目在帕金森病（PDLID）、脆性X染色体综合征(FXS)和药物成瘾中的临床潜力。财务摘要截至2024年6月30日止，- 公司银行结余及现金约13.388亿元- 销售收入约为人民币1.027亿元，共销售84.6万盒华堂宁®- 其他收入约为5510万元，其中拜耳里程碑收益摊销约4780万元- 开支总额约2.459亿元，其中研发开支约1.198亿元前瞻性声明本文包含有关华领医药以及产品未来预期、计划和前景的陈述。该等前瞻性陈述仅与本文作出该陈述当日的事件或资料有关，可能因未来发展而出现变动。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请仔细阅读本文并理解，由于各种风险、不确定性或其他法定要求我们的实际未来业绩或表现可能与预期有重大差异。关于华领华领医药是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁®（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁®已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于不同程度的肾功能损伤（包括未进行透析的终末期肾损）的2型糖尿病患者的口服降糖药物。华领医药将与领军企业拜耳共同推动华堂宁®在中国的商业化推广，以造福糖尿病患者及其家庭。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com新闻免责声明本材料，如为上下文论述的准确性和完整性，提及在中国上市的产品相关信息的，特别是标识或要求，应遵循中国监管机构批准的相关文件。另外，相关信息不应被解读为对任何药物或者诊疗方案的推荐或者宣传，亦不应替代任何医疗卫生专业人士的医疗建议，涉及医疗的相关事宜务必咨询医疗卫生专业人士。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More

Adagene 将于 9 月份参加投资者大会

August 30, 2024
(SeaPRwire) - 圣地亚哥和苏州，中国，2024 年 8 月 29 日 -- Adagene Inc. (“Adagene”)（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物技术公司，致力于改变新型抗体疗法的发现和开发，该公司今日宣布将参加在纽约市举行的几场即将举行的投资者大会。管理层将主持投资者会议，Adagene 的董事长、首席执行官兼研发总裁 Peter Luo 博士将在以下活动中发表演讲： 摩根士丹利第 22 届年度全球医疗保健大会 日期：9 月 6 日（星期五）炉边谈话：美国东部时间上午 7:45 - 8:20 H.C. Wainwright 第 26 届年度全球投资大会 日期：9 月 9 日（星期一）炉边谈话：美国东部时间上午 8:30 - 9:00 2024 年 Cantor Fitzgerald 全球医疗保健大会 日期：9 月 18 日（星期三）炉边谈话：美国东部时间下午 2:30 - 3:00 演示文稿的现场网络直播也将可在该公司网站的 部分访问。网络直播回放将在至少 30 天内提供。 关于 AdageneAdagene Inc.（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物技术公司，致力于改变新型抗体疗法的发现和开发。Adagene 将计算生物学和人工智能相结合，设计出解决全球未满足患者需求的新型抗体。该公司已与信誉良好的全球合作伙伴建立战略合作关系，这些合作伙伴利用其 SAFEbody® 精密屏蔽技术，在科学前沿的多重方法中加以应用。 Adagene 的高度差异化产品线采用其专有的动态精密库 (DPL) 平台，该平台由 NEObody™、SAFEbody 和 POWERbody™ 技术组成，具有新颖的免疫疗法项目。该公司的 SAFEbody 技术旨在通过使用精密屏蔽技术来屏蔽生物疗法的结合域，从而解决与许多抗体治疗相关的安全性与耐受性挑战。通过在肿瘤微环境中的激活，这使得抗体能够在肿瘤微环境中进行肿瘤特异性靶向，同时最大限度地减少对健康组织的靶向非肿瘤毒性。 Adagene 的主要临床项目 ADG126（muzastotug）是一种掩蔽型抗 CTLA-4 SAFEbody，它靶向肿瘤微环境中调节性 T 细胞 (Treg) 中 CTLA-4 的独特表位。ADG126 目前正在与抗 PD-1 疗法联合进行 1b/2 期临床研究，特别关注转移性微卫星稳定 (MSS) 结直肠癌 (CRC)。SAFEbody 平台通过正在进行的临床研究得到验证，可应用于各种抗体疗法模式，包括 Fc 增强型抗体、抗体药物偶联物以及双/多特异性 T 细胞接合剂。 欲了解更多信息，请访问： 。在微信、LinkedIn 和 Twitter 上关注 Adagene。 SAFEbody® 是 在美国、 中国、 澳大利亚、 日本、 新加坡和 欧盟的注册商标。 投资者及媒体联系方式Ami KnoeflerAdagene650-739-9952ir@adagene.com本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

鹰瞳科技2024中期业绩：收入毛利稳健增长

August 30, 2024
EQS 新闻 via SEAPRWire.com / 2024-08-30 / 11:52 UTC+8 8月28日，鹰瞳科技（2251.HK）公布2024年上半年业绩报告，展现了持续稳健的增长态势。 2024年上半年，鹰瞳科技实现营收人民币9371万元，同比增长13.6%。毛利润达到5375.6万元，毛利率为57.4%，公司收入和毛利均实现稳步增长，进一步巩固行业领先地位。 作为全球视网膜影像人工智能领域的领导者和先行者，公司在报告期内通过不断推进AI技术的深度应用，进一步提升了健康管理服务的覆盖和效果。 多元布局显成效，业务增长稳中加速 公司在推进多元化布局的同时，聚焦核心业务，实现可持续增长。报告期内，业务涵盖鹰瞳医疗、鹰瞳健康和鹰瞳眼健康三大板块。鹰瞳医疗和鹰瞳眼健康分别实现了22.1%和22.7%的营收增长。 客户数量和服务网点的显著增加带动了整体业务的扩展。上半年，客户数增至418个，活跃服务网点增至5950个，同比增长78.63%。公司通过SaMD和健康风险评估解决方案服务了296万人次，识别出15,842例重大阳性案例，累计识别重大阳性案例超过7万例，为早期发现和治疗重大疾病做出了重要贡献。 公司还通过Airdoc-AIFUNDUS(1.0)的广泛应用，进一步提升了医疗服务的可及性。医院的覆盖活跃网点数量达到244家，同比增长70.6%；基层医疗机构的覆盖活跃网点数达1533家，同比增长192.0%。检测次数在医院和基层医疗机构均显著增长。此外，公司在全国超过296个体检中心部署了人工智能解决方案，部分体检中心的软件产品复购率超过50%。 全球市场拓展也在同步加速。继获欧盟CE27国的市场准入后，产品已进入马来西亚、新加坡、泰国、阿联酋及南非等国家和地区，国际业务收入同比增长17%。 AI技术突破，视觉训练智能升级 产品的持续迭代升级与科研投入，犹如公司发展的双引擎。既能确保长期竞争力，又可满足客户日益复杂多元的需求，是成功的必要保障。包括但不限于公司与复旦大学附属眼耳鼻喉科医院合作开发的术后屈亮度预测方法，已发表在《白内障与屈光手术杂志（JCRS）》上，为眼科医生提供了更可靠的临床参考。 与上海交通大学医学院附属新华医院合作开发的半监督深度学习模型也取得了显著成果，并发表于《Cell》子刊《iScience》上。该模型大幅减少了数据标注成本，同时保持了优异的分类效果，为临床应用提供了新方案。 报告期内，公司也成功研发了基于普通RGB摄像头的AI眼动技术，并将其整合至视觉训练AI产品中，形成了独具特色的AI视觉训练数字疗法。视觉训练AI产品的升级版本新增了AI眼动和AI训练指导功能，并推出了面向视光渠道的AI视觉训练盒子（VisionBox）。 此外，AIFUNDUS-M多模态眼底相机已完成研发和注册，其硬件、软件、算法及解决方案均实现了全面升级。与此同时，公司还积极推进无创光疗仪的研发，持续拓展产品线。 坚定诊疗一体化战略 致力科技助民 鹰瞳科技深知，企业的卓越还源于对社会责任的深度践行和不懈追求。因此公司积极参与公益项目，如在广东省阳春市开展的大规模慢病筛查项目，为1万名市民提供免费的慢病筛查服务。此外，公司协助华大基因赞助的实验室进行高原病风险监测。报告期内，鹰瞳公益覆盖人数约十万。 展望未来，鹰瞳科技将继续深耕AI技术在医疗健康领域的应用，并推动通用人工智能(AGI)在辅助问诊、疾病检测及个性化医疗建议中的广泛应用，进一步优化产品组合，持续拓宽市场渠道，通过强化技术研发和生产能力，提升全球市场覆盖率。随着长沙制造基地实验室的完善，公司将在眼底视网膜AI、近视防控AI及视觉训练AI产品领域保持竞争优势。 鹰瞳科技坚定推进从检测到诊疗一体化的战略，完善AI健康产业的全面升级，为社会创造更大的价值与可能性，致力“让健康无处不在”的使命。 2024-08-30 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More

现代牙科集团2024年中期股息较去年同期增加33%，数码化个案持续增长 2年复合增长率达56%

August 30, 2024
EQS 新闻 via SEAPRWire.com / 2024-08-30 / 09:53 UTC+8 业绩摘要： 截至2024年6月30日止六个月(「回顾期」)的收益约为17.0亿港元，较去年同期增加约6.3%。欧洲市场占本集团整体收益的48.4%，销售较去年同期增长16.2%。 回顾期内，毛利率约为53.7%；毛利约为9.1亿港元，较去年同期增加约5.4%。 本集团于回顾期内的经调整EBITDA约为3.9亿港元，较去年同期增加 5.1%。 本集团于回顾期内来自核心业务所得溢利约为2.3亿港元，较去年同期增加约7.2%。 本集团于回顾期内的净利润约为2.1亿港元，较去年同期增加约1.9%。 就本集团于回顾期内的EBITDA及净利润而言，该等数字反映：(i)与潜在收购事项有关的一次性成本约279.6万港元；以及(ii)与搬迁深圳及越南生产设施有关的一次性成本约1,021.7万港元。 截至2024年6月30日止六个月的每股基本盈利为22.59港仙。 董事会已宣派截至2024年6月30日止六个月的中期股息每股普通股8.0港仙。 回顾期内，本集团于中国内地生产厂房生产之数码化解决方案个案（海外及国内）增加至约602,485件，较2023年同期增加61.1%，原因为客户持续采用口腔内部扫描仪。 (2024年8月29日，香港) - 全球领先之义齿器材供应商 - 现代牙科集团有限公司(简称「现代牙科」或「本集团」，股份代号: 03600.HK)欣然公布截至2024年6月30日止6个月(「回顾期」) 之未经审核中期业绩。 截至2024年6月30日止六个月，尽管宏观经济环境持续充满挑战，本集团的多维策略及全面的产品组合涵盖了较高价格及合乎成本效益的牙科治疗，让本集团能够把握市场机遇，通过拓展新客户及增加销量，于整个经济周期中实现优于竞争对手的经营表现。义齿行业的整合趋势明显持续，本集团在新添置越南生产设施及东莞二期的生产设施的情况下，将进一步改善其市场定位。 本集团的销量持续增加表明本集团在各市场运营及财务方面的表现稳健。本集团订单量的持续增长、于业内竞争力提升以及与客户保持密切关系等，反映其在相对稳定的经营环境下交出强劲财务业绩的能力。本集团凭借持续稳固的基础，将全力以赴把握未来机遇。 欧洲市场业务 于回顾期间，欧洲市场录得收益约8.2亿港元，较截至2023年6月30日止六个月增加约1.1亿港元，此地理市场占本集团收益总额约48.4%。欧洲市场的收益增加是由于其推出新产品（例如数码化义齿）及先进的数码化流程推动销售订单量增加所致。 本集团已成为提供全面数码化解决方案的先驱，范围涵盖多项微创、美容义齿解决方案以至口腔内部扫描仪及透明矫正器等。本集团已准备好把握牙科行业数码化趋势加速所带来的机遇。本集团将继续通过已建立的具教育价值及数码化，且贴近客户需求的牙科生态系统解决方案，积极从国际及本地竞争对手取得市场份额；并透过不同的境内及境外资源有效地满足我们的客户期望。 北美市场业务 于回顾期间，北美市场录得收益约3.9亿港元，此地理市场占本集团收益总额约22.6%。 回顾期内，客户对数码化牙科的兴趣持续增加，我们在北美地区的大部分业务包括在本地制造的高端产品。凭借我们的中央数码化流程及对区内广泛生产单位的网络监督，我们已准备就绪通过数码化流程来满足客户需求，并专注于提升效率及在整个网络中为客户提供更佳的服务体验。展望未来，本集团旨在使用新设立的越南生产设施，以设立新业务单位专门服务于北美市场的中╱大型连锁牙科诊所客户。 大中华市场业务 于回顾期内，大中华市场录得收益约3.4亿港元，此地理市场占本集团收益总额约19.7%。自2023年下半年起中国内地逐步全面实施带量采购政策起，中国内地市场的销量有所增加，我们在中国内地的业务于回顾期内的销售较去年同期增加9.5%，惟被人民币兑港元贬值2.7%所抵销。然而，此举亦导致中国内地诊所积极于香港推广种植牙治疗（香港患者就诊人数明显减少）。 本集团对此市场的中长期前景感到乐观，特别是在政府最新的采购相关措施中，预计(i)规范义齿价格及建立价格透明度，创造更公平的竞争环境；(ii)让本集团领先的品牌知名度及声望成为客户的主要考虑；及(iii)让本集团从其庞大生产团队中得益及根据顾客或客户有效分配资源。 澳洲市场业务 于回顾期间，澳洲市场录得收益约1.3亿港元，较截至2023年6月30日止六个月增加约364.5万港元，此地理市场占本集团收益总额约7.5%。澳洲市场的收益增加主要由于在牙科行业数码化趋势的推动下市场份额增加及销售订单量增加所致，但部分被澳元兑港元贬值2.8%所抵销。 我们不同的品牌（可提供境内及境外制造的产品）涵盖了从经济及标准至优质╱精品等多种价位的产品，使本集团能够有效地渗透整个澳洲市场。 展望 预期本集团将持续整合义齿市场，董事会认为此整合趋势不可逆转并且将明显持续。尽管全球经济可能面临短期或中期挑战，董事会仍有信心本集团的表现能够优于其竞争对手。在一些竞争对手面临重大不利因素的一年中，本集团依然蓬勃发展，本集团在不确定的经济条件下展现稳固的经营实力，使董事会对集团的发展感到乐观。 展望未来，本集团旨在透过包括战略合作、收购、建立合营企业及╱或合伙企业等机会来巩固其全球领先地位，从而进一步拓展及配合我们的产品发售（特别是我们的透明矫正器产品）、分销及销售网络，藉此将推动我们的业务扩张。本集团将发展成为不单是一站式的义齿供应商，而是一个全面牙科生态系统，以支持我们的顾客需求。本集团在东莞二期及越南的生产设施的投资预计将为本集团提供更多的生产解决方案及选择，从而提高本集团的研发水平及有利进一步升级我们的生产线及产品。 展望2024年，凭借董事会的丰富经验及决心以应对任何短期挑战，本集团已准备就绪，继续善用敏锐的市场触觉全力把握商机，同时保持审慎及谨慎的态度，以保障股东利益。 关于现代牙科集团 现代牙科集团有限公司 (股份代号: 03600.HK) 为全球领先的义齿器材供应商、经销商和顾问，专注于发展迅速的义齿行业为客户提供定制式义齿。我们的产品组合大致可分为三类﹕固定义齿器材，例如牙冠及牙桥；活动义齿器材，例如活动义齿；及其他器材，例如正畸类器材、透明牙套、运动防护器及防鼾器。 现代牙科集团拥有多个备受称许的全球品牌，包括西欧的Labocast、Permadental及Elysee Dental、中国的洋紫荆牙科器材、香港的现代牙科器材、美国的Modern Dental USA 、澳洲、新西兰及爱尔兰的Modern Dental Pacific、新加坡的Modern Dental SG、台湾的Modern Dental TW及马来西亚的Apex Digital Dental等。我们提供稳定和优质的产品及卓越的客户服务，令这些公司品牌能茁壮成长。我们于全球超过23个国家拥有超过80家服务中心及服务逾30,000名客户。 2024-08-30 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More